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ABSTRACT 
 Herpetic stromal keratitis (SK) is an immunoinflammatory corneal lesion caused by 
herpes simplex virus (HSV) infection. This infection, in some cases, can result in a 
chronic immunoinflammatory lesion that is the most common cause of infectious 
blindness in the developed world. Studies in animal models have revealed that SK lesions 
are orchestrated mainly by IFN-gamma producing CD4+ T cells (Th1) and neutrophils 
that infiltrate the corneal stroma. 
 The first part of this dissertation (I) reviews literature on HSV induced corneal SK 
immunopathology and the role of Tregs in viral infections. It also focuses on the 
understanding of HSV-1 induced immunoinflammatory events in the corneas, particularly 
T cells. The next three parts (II-IV) concentrate on the inflammatory and regulatory 
mechanisms that happen following HSV-1 infection in both, the cornea and secondary 
lymphoid tissues, and the use of therapies to control the inflammatory immune responses 
and the immunopathological lesions. Results in Part II evaluate the role of regulatory T 
cells in controlling the progression of the inflammatory lesions during the clinical phase 
of SK and the mechanisms used by Tregs to control immunopathology. Results of the 
third section show that modulating the aryl hydrocarbon receptor signaling by the use of 
TCDD shifts the balance toward regulatory T cells, mainly by inducing apoptosis on T 
effectors and generating Tregs, which results in diminished severity of SK. The fourth 
section describes the role of lymphotoxin-alpha (LT- ) after HSV infection, a 
proinflammatory molecule that can be secreted by or expressed in some subsets of T 
cells. Depletion of LT-  positive T cells, by the use of a monoclonal antibody seemed to 
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be an effective approach to terminate Th1 responses thereby reducing the severity of 
lesions. 
 Collectively, in these studies, experiments were designed to understand the role of 
regulatory T cells during the disease and to control the progression of ongoing 
inflammatory reactions by developing different therapeutic strategies for SK, the most 
common cause of infectious blindness in the Western World. 
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INTRODUCTION 
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Herpes Virus Type 1 and Stromal Keratitis 
 
 Herpetic Stromal Keratitis is an immunoblinding ocular lesion in the normally 
transparent cornea, caused by herpes simplex virus (HSV) infection. Infection can be 
acute and resolved if treated. However, in some cases it can result in a chronic 
immunoinflammatory lesion that is the most common cause of infectious blindness in the 
developed world.  The transmission of HSV infection occurs through contact with 
mucosal surfaces or abraded skin, and the oropharyngeal mucosa is the most common site 
of infection [1]. Initially, HSV-1 replicates in the epithelial layer, at the site of primary 
infection, followed by retrograde migration of the virus to the trigeminal ganglion (TG). 
It is in the TG where the virus becomes latent and is maintained in the host [1-3]. During 
latency, the virus does not replicate, however, the host can undergo different conditions 
such as stress or immunosuppression, resulting in reactivation of the virus [4, 5]. Once 
the virus is reactivated, it usually migrates to the initial site of infection causing 
inflammatory reactions in that site [2, 3].  
 When that site is the eye, the response generated can cause a subclinical or clinical 
inflammation. If the disease becomes severe, a chronic immunoinflammatory syndrome 
in the corneal stroma may happen, which can generate what is called stromal keratitis 
(SK) that can lead to blindness [6].  The human SK pathogenesis is very complex, but it 
is mainly thought to be a CD4
+
 T cell inflammatory reaction accompanied by the growth 
of newly formed blood vessels [6]. Most of our knowledge is based on studies that use 
the mouse as an animal model. In different animal models of infection, CD4
+
 T cells 
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mainly orchestrate lesions generated in the eye. Moreover, stromal lesions do not occur in 
animals that lack T cells, but lesions can be restored with adoptive transfer of CD4
+
 T 
cells [7]. A major unresolved issue is to define the antigen specificity of the CD4
+
 T cells 
involved in orchestrating HSK. Because peptides or tetramer reagents that identify T cell 
specificity are not readily available, specificity of the cells that cannot be studied. 
However, specificity is suspected, but it is thought that bystander T cells are also 
involved. We believe that these bystanders can be stimulated, and generate pro-
inflammatory components that could further contribute to HSK. Another hypothesis is 
that SK lesions come from the presence of autoantigens that are being unmasked in the 
cornea, and that will cause autoreactive cells to mediate autoimmunoinflammatory 
responses. Even the virus itself could do molecular mimicry for the autoantigens [8]. 
Moreover, SK lesions are also marked by the development of pathological angiogenic 
responses in the cornea that can be extensive and further impair normal vision [7, 9]. 
Thus the clinical phase of SK pathogenesis involves at least two significant events, the 
migration of CD4
+
 T cells in the corneal stroma and the development of new blood 
vessels in the normally avascular cornea. 
 Currently, treatment of SK involves a combination of anti-viral and 
antiinflammatory drugs [10-12]. However, to control the chronic inflammatory reaction, 
long periods of anti-inflammatory drugs, particularly corticosteroids, are administered. 
These corticosteroids can have serious side effects such as risk of cataract formation and 
glaucoma [10-12]. Additionally, corticosteroids may also promote HSV replication, 
which will worsen SK lesion severity [13]. Therefore, there is a need for the development 
of new and alternative therapeutic strategies to control SK immunopathology. 
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Understanding the different mechanisms responsible for the development of SK lesion 
could shed light on possible targets for better control of SK pathology. 
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Pathogenesis of SK 
 Different animal models are used to study SK. Balb/c or C57BL6 mice corneas 
can be infected with specific strains of HSV-1. The most reproducible system is the 
infection of the mouse’s eye with the RE strain [8], which we use in our laboratory. 
Following infection of the eye, the virus replicates in the epithelial cells. This process 
lasts around 5-6 days (Figure 1) [7]. Early after infection, innate inflammatory cells also 
infiltrate the cornea. These innate cells are mainly neutrophils, which migrate to the 
cornea due to the chemokine milieu generated after the infection [7, 14]. This infiltration 
of neutrophils happens in a biphasic manner, peaking first on day 2 post-infection (p.i) 
and with a second peak around day 11 p.i [7, 14, 15]. Neutrophils play a protective role 
during their first wave by collaborating in viral clearance [16] and provide anti-viral 
defense by producing reactive oxygen species (ROS), TNF-α and IFN-γ. However, the 
second wave contributes to corneal tissue damage [14, 15], because neutrophils can also 
provide conditions for the consequent inflammatory response by releasing mediators such 
as IL-1β, IL-8, IL-12 and TNF-α. Moreover, neutrophil secreted nitric oxides may 
unmask corneal antigens, which may be recognized by T cells, providing a continuous 
influx of reactive T cells. In addition, neutrophils also secrete matrix metalloproteinases 
(MMPs) such as MMP-9, which breaks the stromal matrix and the VEGF soluble 
receptor [15] contributing to neovascularization of the cornea. Other inflammatory cells 
are evident by 24 h pi and these include natural killer cells (NK), gamma delta T cells 
( -T cell), dendritic cells (DC), and macrophages; but neutrophils are always the most 
prominent cells infiltrating the cornea [8]. NKs, just like neutrophils, are believed to 
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function to abort infection [7]. On the other hand, DC are likely involved in transporting 
viral antigen to the draining lymph node and initiating adaptive immune responses. 
Moreover, some DC subtypes and macrophages could be a source of lesion modulating 
molecules such as interferons, transforming growth factor beta (TGF-β) and IL-10 [8]. 
-T cells likely participate in initiating angiogenesis since they produce IL-17A that acts 
as an inducer of VEGF [17]. VEGF-A, which is a proangiogenic protein, is evident in the 
cornea within 24 hrs and is mainly produced by epithelial cells or the stromal cells after 
infection [18]. IL-1 and IL-6, produced by infiltrating inflammatory cells, are the other 
inducers of VEGF. Furthermore, uninfected corneal epithelial cells become the 
significant producers of IL-6 and IL-1β [7]. However, it is still poorly understood how 
the uninfected corneal epithelial cells are programmed to produce these cytokines. One 
possible explanation for this is that pathogen associated molecular patterns (PAMPs) 
expressed by virus-infected cells or perhaps extracellular virus itself could activate 
different pattern recognition receptors (PRRs) [7, 19, 20]. Moreover, IL-1β acts in a 
paracrine fashion on uninfected corneal epithelial cells and stimulates the production of 
IL-6 [21, 22]. IL-6 also triggers the synthesis of CXCL8, which is involved in neutrophil 
influx at the site of inflammation. The formation of new blood vessels starts really early 
after infection. These blood vessels sprout from the normal vasculature at the limbus, and 
in later stages can almost reach the central cornea. However, this extent of corneal 
vascularization is rare in human SK [8].  
 The stromal lesions that occur in the eye are immunopathological events that are 
mainly orchestrated by T cells, mainly CD4
+
 T cells. They appear in the cornea around 
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day 7 p.i., and their peak responses happen around day 14 p.i [7]. Studies in an animal 
model of SK have revealed a critical contribution of CD4
+
 T cells of the Th1 subset as 
principal orchestrators of SK lesions [23, 24]. Unfortunately, appropriate peptides or 
tetramer reagents to identify T cell specificity have not been used and are not readily 
available [8]. Antiviral specificity is suspected to be one of the targets for T cells, but 
activated T cells of other specificities due to bystander activation are present in lesions 
and these are hypothesized to also play an important role [10]. Moreover, these 
bystanders can be stimulated to generate pro-inflammatory components that further 
contribute to SK. Another hypothesis, mentioned before, is that development of SK 
lesions could be the consequence of autoantigens being unmasked in the cornea, driving 
autoreactive cells to mediate an autoimmune inflammatory reaction [25]. An extension of 
this idea is that the virus itself may act as a molecular mimic for some of these 
autoantigens [26]. However, the concept has never been independently confirmed and has 
been experimentally refuted [10]. 
 As mentioned before, Th1 cells are the major subtype of CD4
+
 T cells infiltrators. 
However, different subsets of CD4
+
 T cells infiltrate the corneal stroma after infection. 
Th1 cells infiltrate the cornea along with FoxP3
+
 regulatory T cells (Tregs) [24, 27]. 
Tregs are CD4
+
 Foxp3
+
 T cells that can suppress and control immune responses and will 
be discussed in the next section. Another type of CD4
+
 cells that infiltrate the cornea is 
Th17 cells. Th17 cells become more evident after day 15 p.i, and as Th1 cells, are 
thought to have a proinflammatory role in SK pathogenesis, although these never 
outnumber Th1 cells [28]. Our long-term hypothesis is that Tregs could be helping in the 
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resolution of the clinical lesions after HSV-1 infection. Our laboratory has previously 
reported that depletion of natural Tregs (nTregs) prior to HSV-1 ocular infection 
increased the severity of SK in the infected corneas [27]. Moreover, we have shown in 
other studies that expanding Tregs or transferring them from the onset of lesion induction 
resulted in diminished SK lesion scores. In general, results from different reports indicate 
that Tregs play a beneficial role to minimize and modulate the severity of viral-induced 
immunoinflammatory reactions. Since murine SK lesions do not resolve spontaneously, a 
novel therapy that uses Tregs or targets them could be of interest. 
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Tregs and immunopathology 
 Vertebrates are frequently infected with different viruses throughout their life but 
in most cases, infections are resolved due to the existence of different defense 
mechanisms. Nevertheless, in some instances, infections can cause substantial tissue 
damage, either by the presence of the pathogen or to the immune response generated 
towards it, as we have described in the above sections. It is important to understand that 
fighting and surviving an infection requires the generation of immune responses, but 
these need to be controlled. There are multiple regulatory mechanisms, and these include 
different molecules and cells with regulatory roles [29]. There are different types of 
regulatory T cells, however, the two big subtypes are natural and inducible Tregs [30]. 
Natural Tregs are CD4
+
 T cells generated in the thymus, whereas inducible Tregs 
(iTregs) are derived from naïve, or occasionally committed, CD4 T cells exposed in an 
appropriate environment of cytokines (such as TGF-  and retinoic acid), cognate antigen 
and co-stimulation to become Treg [31]. The importance of Tregs is that the global 
balance between effector and regulatory mechanisms/Tregs can determine the outcome of 
an infection [32]. This can range from uncontrolled pathogen growth, which can lead to 
the host’s death, to complete elimination of the microorganism. Most of the Foxp3+ Tregs 
are considered to be thymus-derived and are largely reactive to a range of self-antigens 
[33]. These cells are involved in preventing and constraining autoimmunity, however 
they may also participate in responses to foreign antigens and tumors. Moreover, 
regulatory cells may function beneficially to control tissue damage caused by different 
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factors such as auto-reactivity, allergies, allotransplants, as well as responses to different 
tissue damaging pathogens [34].  
What are Tregs? 
Natural Tregs  
 Natural Tregs are CD4
+
 T cells that develop in the thymus, express Foxp3 and 
respond to self antigens [32], although it is believed that they can also respond to 
microbial antigens, acting at the infection site as regulators. Its differentiation and 
function are controlled by the X chromosome-encoded transcription factor Foxp3
+
. 
Inducible Tregs  
 Inducible Tregs are also known as adaptive Tregs. This type of cells develops in 
peripheral lymphoid tissues [30].  There are different types of iTregs, however we will 
only focus on Foxp3
+
CD4
+
 iTregs. These iTregs are naive T cells that in the periphery 
can acquire Foxp3, express it and become Tregs [35]. These cells originate from Foxp3
-
 
CD4
+
 T cells that under specific conditions become Foxp3
+
 and also acquire a regulatory 
role. These cells can be induced under different conditions but they have 3 main 
requirements: TCR stimulation, TGF-  and IL-2, for their in vivo and in vitro generation 
[31]. These Foxp3
+
 iTregs can also be generated in the gut in response to microbiota and 
food antigens [36], after the induction of oral tolerance [37], and in chronically inflamed 
tissues [37].  During infection, not only proinflammatory molecules are produced, also 
some anti-inflammatory molecules are upregulated such as TGF- . Furthermore, some 
pathogens can target sites in which TGF-  is highly produced, for example the gut, the 
skin and the eye [38].  
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Treg induction 
 In our laboratory, we have already shown that Tregs can affect the magnitude of 
antiviral immunity and therefore the outcome of the infection and of the disease [27, 39].  
This effect exerted by Tregs can contribute to persistence of the virus and therefore 
chronic disease, but it also controls excessive collateral tissue damage in the eye.  In 
different viral infections, the virus can induce Tregs and they do so to delay or prevent 
early host destruction. Viruses, have developed different and multiple strategies to 
manipulate immune responses (innate and adaptive), and to favor a Treg cell environment 
acting at different levels: Treg cell priming through the manipulation of APCs, Treg 
recruitment by creating a specific cytokine and chemokine milieu, and Treg survival [32]. 
The main role of Tregs is to control exacerbated immune responses and therefore, the 
degree of immune-mediated pathology [40]. Different studies have shown that signals 
associated with tissue damage trigger nTreg responses controlling innate cells as well as 
effector T cells [40]. In general highly inflammatory environments such as those found in 
acute infections usually do not favor the induction of Tregs [41]. On the other hand, 
chronic infections have a perfect environment for Treg induction, and survival. During 
infections, Tregs can be induced in different ways. The majority of nTregs are self-
reactive and control autoimmunity [42], however, their TCRs can be cross-reactive with 
microbial antigens, and the presence of a pathogen can induce Tregs directly or 
indirectly. Specificity of Tregs needs further research but studies have shown that 
removal of Tregs prior to infection changes the outcome of the disease, and of the 
immune response and immune pathology [27, 39, 43]. As an example, when Tregs were 
removed prior to HSV-1 ocular infection, ocular immunopathology as well as immune 
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responses were increased [27]. Different effects after removal of Tregs have been 
observed in different viral models of disease, such as RSV, WNV, and Friend retrovirus 
[42].  
 An option for Treg induction would be the activation of nTregs in a non-specific 
manner, through the use of Toll-like receptors (TLRs). This can happen either by ligands 
expressed by the microbes such as PAMPS [41], ligands derived from tissue damage 
known as damage associated molecular patterns (DAMPS) or indirectly through DCs 
[41]. Tregs as well as T effectors have been shown to express almost all TLRs [44], 
indicating that TLR signaling could have an effect on the function of these cells. 
Different TLR ligands can act on nTregs but outcome varies. A direct ligand activity has 
been reported for HCMV, where its gB protein can act as a ligand for TLR2 [45]. 
Another case of immune activation was also shown in a mouse model of RSV, where the 
studies indicated that TLR2 is involved in RSV recognition and immune activation [46]. 
HSV has also shown TLR2 activity [19]. TLR4 stimulation also causes nTreg to 
proliferate [47]. On the other hand, other TLRs such as TLR8 and TLR9 have been 
shown to suppress nTreg activity. In general, there is a concept that TLR2, TLR4, and 
TLR8 downregulate the function of Treg [48-51]. Furthermore, TLRs are mainly found 
on APCs [52]. These TLR can also recognize PRR from viruses and cause the secretion 
of specific cytokines, which in turn can determine the type of immune responses or the 
expansion of a specific T cell subset. Activated DCs can activate T cells, which in turn 
will produce molecules such as IL-2 and IL-15, which are powerful growth factors for 
Tregs [53, 54]. Moreover, Tregs can also be induced indirectly through DCs [41].  
 Another way microorganisms can lead to Treg cell conversion is by causing 
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apoptosis of cells at the site of infection. Clearance of apoptotic bodies can lead to the 
development of Treg cells [55]. Moreover, when DCs and macrophages engulf apoptotic 
cells, they can secrete TGF-  [56], which as we mentioned before, induces the generation 
of Tregs [56]. In addition, viral infections can induce the production of molecules such as 
heat shock proteins (HSPs) or -defensins, which can act as TLR4 ligands [57, 58]. 
These molecules are generated after viral infections such as in HSV [7].  Other proteins 
too, are detected by TLRs. For example, self-proteins such as the extracellular matrix 
component “hyaluroan” can signal through TLR2 or TLR4 [41] and self DNA or self 
RNA can activate TLR7 or TLR9 [59]. These self-proteins and nucleic acids are often 
released after tissue damage from cells undergoing necrosis, which happens during viral 
infections. 
 There are other non-TCR mechanisms besides TLRs by which viruses can trigger 
nTregs. During infection, some of the downstream effects of inflammatory responses are 
associated with anti-inflammatory effects such as TGF-  production. In addition, TGF-  
can also be produced by infected cells or by cells, which the virus is in contact with [60] 
Cytokines and other molecules produced during infection, such as IL-2, TNF-  [61], and 
-melanocyte [62], have also been proven to boost nTreg. Moreover, during 
inflammatory responses, a family of molecules known as galectins are also produced. As 
an example galectin 9 binds to the TIM-3 receptor on T effector causing apoptosis, 
whereas on nTregs causes expansion and activation. This has been shown in different 
models of infection. In our model, the Tim 3-galectin 9 pathway has been linked to 
reduced and more controlled immune responses [63], and treatment with galectin-9 was 
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able to decrease HSV-1 immunopathology.  
 Another non-TCR mechanism that increases nTregs is HVEM. HVEM, is a tumor 
necrosis factor receptor super family member which interacts with the gD protein of 
HSV-1 to facilitate cell entrance. Cells of the immune compartment constitutively 
express HVEM, and previous reports have demonstrated that engagement of HVEM with 
different ligands causes T cell expansion and activation [64]. Studies from our lab 
demonstrate that HSV-1 infection in the footpad increases the frequencies and numbers 
of Tregs and also the expression of HVEM on Tregs. Our hypothesis is that HSV-1 could 
be using HVEM to increase nTregs and diminish immune responses evading the immune 
system (Sharma S & Rouse B.T manuscript under preparation). 
 From these studies we can conclude that viral infections can trigger the activation 
and expansion of nTregs though different mechanisms in a specific and non-specific way. 
This could mean that viruses have evolved using host factors to survive. These 
mechanisms are use by viruses on their advantage, which in turn will generate an 
environment of immunosuppression, making them capable of evading immune responses 
and surviving in the host. 
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Viral infections, Tregs and immunopathology 
 Humans are frequently infected with different viruses throughout their life, and in 
most cases infections are overcome without complications. However, some infections can 
cause substantial tissue damage, and this is not always due to the infection itself but to 
the immune response generated. Surviving an infection requires the generation of an 
immune response, which ideally will control and eliminate the pathogen while limiting 
collateral tissue damage. Almost all viral infections cause the recruitment and activation 
of inflammatory cell types, that at the same time, release proinflammatory molecules that 
can induce tissue damage. This happens in innate responses as well as in adaptive 
immune responses [42].  
 The first damage found after a viral infection is the killing of the infected cells. 
This results in secretion of their cellular contents such as proteases and lysosomal 
enzymes that will digest the extracellular matrix of different cells and will create an 
inflammatory milieu, which will attract innate cells from the immune system. 
 Innate cells have surface as well as intracellular receptors that are activated after 
viral infections.  The main receptors that activate innate immune cells after infection are 
TLR, nod like receptors (NLRs) and retinoic acid inducible gene I (RIG-I). Viral 
infections usually activate intracellular TLRs known as “endosomal TLRs”, which 
recognize viral nucleic acids and double-stranded RNA, these are TLR3, 7, 8 and 9. On 
the other hand, NLRs recognize viral DNA genomes, and RIG-I recognizes viral genomic 
RNA or RNA encoded by genomic DNA.  The activation of these receptors provokes the 
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production of proinflammatory cytokines as well as type I interferons. These will also 
cause the activation and migration of cells that form part of the adaptive immune 
responses [42].   
 Adaptive immune responses have an important role in tissue damage. T cells have 
been shown to cause tissue damage in multiple viral diseases. Damage can originate from 
the different subsets of T cells. CD8
+
 T cells are the main cause of damage to the liver in 
HBV and HCV. In other diseases, Th1 can contribute to tissue damage such as in HSV-1. 
Th17 are also known to be a factor in some chronic inflammatory viral infections such as 
HIV, flu and HCV. In these type of responses, Th17 cells attract neutrophils which will 
cause damage by secreting tissue damaging molecules. In our model too, we have shown 
the contribution of Th17 cells in corneal SK, but the number Th17 cells appeared to be 
increased in more chronic stages of the disease, and was always lower than Th1 total cell 
numbers [28]. 
 In most cases, tissue damage is modest, however this is not always the case. The 
role of Tregs is to counteract a possible excessive tissue damage following viral 
infections by inhibiting the task of other cell types. At first, the induction of Tregs during 
the course of a viral infection was considered to have a detrimental effect, because it was 
thought to promote virus persistence. However, later studies demonstrated that Tregs 
could protect the host against immunopathology.  
Tregs and viral infections- different outcomes 
 As mention before, the role of Tregs is to control the extent of immune responses. 
Because immune responses can become pathological, Tregs could control the extent of 
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immune-mediated pathology. A role of Treg is to respond against tissue destruction, 
limiting tissue damage [65].  A key to the outcome is the balance of Tregs and effector 
cells. 
 Acute infections are those where clinical signs occur short after infection and end in 
death or full recovery. With some acute infections, Tregs expand and become activated. 
This has been shown in diseases such as experimental HSV-1 [66], HSV-2 [67], RSV 
[68], and influenza virus infections [69].  
 In the case of HSV-1 infection, Treg presence has been shown to control SK 
immunopathology. The mechanism of Treg controlling SK was by constraining the 
activation of Foxp3- T cells, and in general by suppressing effector T cell responses in 
the DLNs [27]. However, these studies were done by depleting Tregs prior to infection. 
Other studies from our lab have demonstrated that disease can be modulated with the 
transfer of Tregs or with therapies that boost regulatory T cell populations [70-74]. In the 
case of HSV-1 footpad infection, Tregs control CD8
+
 cell proliferation and effector 
function, favoring pathogen expansion [39]. On the other hand, in a model of HSV-2, 
Tregs were shown to facilitate early immune responses by assisting in the coordination of 
the trafficking of immune effector cells to the infected tissues, and the absence of Tregs 
exacerbated viral load in the vaginal mucosa, causing the development of severe lesions 
and hind limb paralysis 4 to 5 days earlier than in Treg-sufficient mice. In this 
manuscript, the authors claimed that Treg depletion also favored early viral replication in 
the liver during LCMV infection [20]. This group implied that Tregs may facilitate the 
movement of effectors to infection sites, where they could control and eliminate the 
virus. A similar outcome was reported in a model of RSV infection [75]. These 
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differences could be attributed to different infection models and different viruses.  
 Another condition where Tregs may be involved in HSV pathogenesis is during the 
inflammation produced in the CNS [76-78]. In this case, neurons are infected with the 
virus, but are not killed by the activated CD8
+
 T cells [78]. It would be interesting to 
study if removal of Tregs could have consequences in CD8
+
 T cell responses and neuron 
disruption. In a recent paper published by Reuter et al [79], the role of Tregs was 
investigated in a model of virus persistence in the CNS by the use of measles virus. In 
this model, Tregs expanded during the persistent phase of the viral infection. When Tregs 
were depleted, an increase of virus-specific CD8
+
 effector T cells in the brain occurred, 
causing a reduction of the persistent infection. Contrary to our findings, the authors imply 
that infected neurons are target cells of CD8
+
 lymphocytes, and that brain infections to 
some extent can be inhibited by CTL activity. However, they did not study the 
immunopathological effects of Treg depletion. 
 Events happening during the acute phase of some infections can have an effect on 
the pattern of a disease as well as the chronicity of it. An important factor is Treg 
responses. For example, in HCV a small percentage of people can control the infection 
and clear the virus. However, most people suffer chronic HCV and end up in liver failure. 
Foxp3
+
 Tregs increase in patients infected with HCV, and studies in vitro show that their 
removal results in enhanced effector immune responses, suggesting that initial Treg 
responses could be suppressing effectors needed for viral clearance, and therefore leading 
to chronicity of disease [80]. In some diseases, Treg expansion can be correlated to the 
outcome of disease. For example, old world monkeys resist SIV whereas new world 
monkeys are susceptible. It has been observed that African Green monkeys develop a 
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more rapid Treg response, which could inhibit T cell hyperactivation. T cell 
hyperactivation has been hypothesized to cause CD4
+
 T cells more susceptible to 
infection and therefore to cell depletion, which could be causing monkey death. 
Therefore, the degree of hyperactivation is a powerful prognosticator of AIDS 
progression and death [81-86]. However, elevated Treg presence results in poor viral 
control and maintenance of infection, which can lead to chronic tissue damage [42, 81]. 
As commented in the above models of infection, in most of the cases, Tregs usually 
control immune responses and therefore reduce collateral tissue damage done by immune 
cells. However, this can lead to chronicity of the infection. 
 The importance of the generation of Tregs responses is trying to find a balance 
between Tregs and effectors to avoid immunopathology. However, in some situations, 
this control exerted by Tregs could contribute to a situation where impeding 
immunopathology leads to the persistence of the virus. Most viruses that establish 
chronic infections evade destruction by CD8
+
 T cells, and Tregs are thought to be 
involved in this immune evasion. In the case of mice infected chronically with Friend 
leukemia virus, there is an increase in the number of Tregs [87]. This increase, affects 
CD8
+
 T cell responses. When Tregs are removed, CD8
+
 T cell effector functions are 
restored, and viral loads are reduced [88-90]. It has also been shown that transient 
depletion of Tregs during a chronic retroviral infection with FV allowed exhausted CD8
+
 
T cells to regain antiviral functions [91] decreasing viral loads. This implies that Treg 
mediated immunosuppression can be a significant factor in the maintenance of several 
chronic viral infections and that Treg-targeted immunotherapy could be a valuable 
approach to treat chronic infectious diseases.  
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 Tregs also appear to play a role in the control of chronic viral hepatitis. HCV and 
HBV are the most common cause of liver disease in the world and failure to control the 
infection results in an immunomediated necroinflammatory disease [41]. In patients with 
chronic HBV, Foxp3
+
 T cells are highly increased in the periphery and liver [41] and this 
also correlates with viral loads. Barboza et al [92] showed a positive correlation between 
IL-10 producing Foxp3
+
 T cells, which expanded due to the exposure to the viral antigen. 
As mentioned before, Treg responses in the acute phase of infection have been linked to 
the chronicity of the disease, and reports show that patients with chronic HCV infection 
have significantly higher proportions of Tregs in their blood than healthy people or than 
those who had recovered from acute HCV [93, 94]. An explanation is that virus-induced 
Tregs can suppress CD8
+
 T cell responses and avoid the clearance of the virus [95]. 
However, the role of Tregs during the chronic phase of the disease is important in 
controlling immunopathology. CD8
+
 T cell responses in chronic HCV patients can induce 
cytolysis of liver cells and therefore cause immunopathology [96]. Moreover, reduced 
levels of CD25
+
 CD4
+
 T cells have been associated with higher incidence of cirrhosis and 
increased mortality [97]. However, other publications have correlated the presence of 
Tregs in the liver with fibrosis [98]. Different and numerous studies have indicated the 
involvement of Tregs in HIV infection.  During the disease, there is a progressive loss of 
CD4
+
 T cells, chronic immune activation and defects in multiple cell types [99]. Some of 
the studies suggest that Tregs can limit HIV and SIV T cell responses, limiting the ability 
of these cells to control viral replication. Studies in vitro have shown that anti-HIV 
responses were increased after the removal of Tregs from peripheral leukocytes [100-
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104].  Moreover, it is thought that HIV may provide a survival/proliferative signal to 
Treg cells [105]. Again, the consequences of Treg expansion after HIV infection can be 
beneficial, by suppressing generalized T cell activation, or detrimental by limiting T cell 
responses against HIV and therefore, promoting the persistence of the virus within the 
host. 
 In summary, Tregs have different roles depending when they act and in which 
disease. The effect of Tregs is necessary to prevent immunopathology, but a balance 
between the host, immune response and the virus needs to be established. As discussed 
above, the equilibrium between effector cells and regulatory mechanisms can determine 
the outcome of an infection, which can be beneficial or detrimental to the host and 
pathogen. The over control executed by Tregs can lead to the maintenance and survival 
of a pathogen and therefore long-term persistence in the host. Some pathogens even 
induce Tregs favoring their maintenance. However, this could lead to chronicity or even 
worse, the uncontrolled replication of the pathogen compromising the host’s survival. On 
the other hand, regulatory responses are needed, since their lack can lead to 
immunopathology and tissue damage. 
 
 
 
 
 
 
 
  22 
 
Current treatment options 
 Currently the therapeutic agents used for treating SK include the administration of 
antivirals and corticosteroids [10, 106, 107]. However, these drugs have numerous 
adverse effects. Animal studies in the mouse model of SK have demonstrated the 
importance of T cells in SK pathogenesis. Tregs are shown to be involved in controlling 
the ongoing inflammatory processes in the cornea [27]. Studies from our laboratory 
suggest that depletion of Treg from the mice prior to infection results in more severe SK 
lesions [27]. For therapeutic purposes, it would be preferable to boost Tregs or shift the 
balance toward regulators to decrease SK immunopathology during the clinical phase of 
the disease. Another option would be to target specifically effector T cells without 
affecting Tregs. It is important to highlight that many studies have advocated the 
differential susceptibility of Tregs to depletion and apoptosis inducing strategies. Thus, it 
was shown that TCR stimulated Tregs were less susceptible to Fas-Fas-L induced 
apoptosis than TCR stimulated conventional T effectors [108]. Other treatments can also 
deplete T effectors while sparing the Treg population [109, 110]. Therefore, in the SK 
model of disease, we have evaluated two different ways of shifting the balance toward 
regulatory cells by either targeting both T effectors and Tregs by the use of TCDD, or by 
specifically depleting T effectors with a mAb known as anti-lymphotoxin- . 
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Conclusions  
 SK is a chronic immunoinflammatory lesion in the cornea with a complex 
pathogenesis. Discoveries of novel pathways and the role of infiltrating cells in the 
pathogenesis of the disease would provide new targets for the design of new therapies. 
Because T cells have a major role in SK pathogenesis, approaches that either inhibit, or 
eliminate Th1 responses, boost Tregs, or shift the balance toward Tregs would be of 
interest. 
The work described in this dissertation evaluates the effects of some of these 
strategies on the modulation of SK lesion severity. First, the role of Tregs during the 
clinical phase of the disease is evaluated and characterized by specifically depleting those 
cells that express Foxp3. In the third chapter, modulation of the aryl hydrocarbon 
receptor (AhR), a transcription factor expressed in different subsets of T cells was studied 
by the administration of TCDD. This treatment was administered once, and controlled SK 
immunopathology by shifting the balance of T cells toward regulators. In the forth 
chapter, we studied the possibility of controlling SK by modulating lymphotoxin- -
mediated inflammatory pathways. Treatment of mice with a depleting anti-LT-a 
monoclonal antibody (mAb) during the clinical phase of the disease significantly 
attenuated SK lesions by specifically targeting Th1 cells. 
Accordingly, modulating and targeting T cells responses during SK can be 
beneficial in preventing and/or controlling SK immunopathology. Moreover, these 
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approaches could be used individually or in combination with other existing therapies to 
resolve SK, an important cause of infectious blindness in the Western World. 
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FIGURE 1.1. Principal events in HSV induced cornal SK pathogenesis 
Following HSV infection of the cornea, replicating virus is detectable in the cornea until 
day 7 pi. Neutrophils infiltrate the cornea in a biphasic influx peaking first on day 2 p.i 
and then around day 11 p.i. Development of new blood vessels from existing limbal 
vessels starts as early as day 1 pi. . Influx of pathogenic CD4+ T lymphocytes occurs in 
the clinical phase around 7-9 days p.i. 
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Research described in this chapter is a slightly modified version of an article published in 
Journal of Immunology by Tamara Veiga Parga, Amol Suryawanshi, Sachin Mulik, 
Fernanda Gimenez, Shalini Sharma, Tim Sparwasser and Barry T Rouse. 
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Abstract 
 Ocular HSV-1 infection can result in SK, a blinding immunoinflammatory lesion 
that represents an immunopathological response to the infection. CD4
+
 T cells are the 
main orchestrators, and lesions are more severe if the regulatory T cell response is 
compromised from the onset of infection. Little is known about the role for Foxp3
+ 
CD4
+
 
Tregs during ongoing inflammatory reactions, which is the topic of this report. We used 
DEREG mice and depleted Treg at different times after infection. We show that lesions 
became more severe even when depletion was begun in the clinical phase of the disease. 
This outcome was explained both by Treg influencing the activity of inflammatory 
effector T cells at the lesion site, as well as an effect in lymphoid tissues that led to 
reduced numbers of effectors and less trafficking of T cells and neutrophils to the eye. 
Our results demonstrate that Treg can beneficially influence the impact of ongoing tissue 
damaging responses to a virus infection and imply that therapies that boost Treg function 
in the clinical phase hold promise as a modality to control a lesion that is an important 
cause of human blindness. 
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Introduction 
 Ocular infection with HSV-1 can result in a chronic immunoinflammatory lesion in 
the corneal stroma, which is a significant cause of human vision loss (1, 2). Studies in 
animal models have revealed that SK lesions are orchestrated mainly by IFN-  producing 
CD4
+
 T cells (Th1) (3, 4) and to a lesser extent by IL-17 producing CD4
+
 T cells (Th17) 
(5). Lesion severity is also subject to modulation by several host-derived factors, which 
include IL-10 (6), some galectins (7, 8), microRNAs (9), as well as by Treg (10, 11). 
Thus removing or expanding Treg from the onset of lesion induction results in 
exacerbated or diminished lesions, respectively (10, 12). The role for Treg in modulating 
lesion severity in multiple autoimmune diseases is well established (13, 14), and Treg are 
suspected to play a similar role in several chronic infections, which include hepatitis C 
and some of the lesions caused by HIV (15, 16). However, few if any studies have 
evaluated the role of Treg in an infection-induced lesion by removing them during the 
ongoing disease process. A recent study did perform such a study removing Treg several 
days after intracerebral infection with measles virus (17). They showed that viral 
clearance was accelerated, but did not evaluate any changes in tissue damage. 
 In the present report, we have evaluated the lesion modulating consequences of 
Treg removal after lesions have commenced in a system where tissue damage is caused 
by an immunopathological response to infection. Our results show that Treg depletion 
resulted in increased lesion severity with the effect less evident as the depletion was 
delayed further from the time of infection. The consequences of Treg removal appeared 
to have two explanations. These were inhibitory effects at the lesion site, as well as 
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effects in lymphoid tissues that reduced the migration of inflammatory cells to the tissue 
lesion. Our results indicate that Treg play a beneficial role to minimize and modulate the 
severity of viral-induced immunoinflammatory reactions. This could mean that 
expanding Treg function could represent a promising approach for therapy. 
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Materials and Methods 
Ethics statement 
 This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Research Council. All 
animals were housed in Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC)-approved animal facilities. The protocol was approved by the 
Institutional Animal Care and Use Committee of the University of Tennessee (PHS 
Assurance number A3668-01). HSV-1 eye infection was performed under deep 
anesthesia (avertin), and all efforts were made to minimize animal suffering. 
Mice, virus, and cell lines 
 Breeder pairs of DEREG mice on C57BL/6 background were provided by Dr. 
Tim Sparwasser (Munich, Germany), and additional mice were bred in the Walters Life 
Sciences animal facility at the University of Tennessee, Knoxville. For the experiments, 
female 5 to 6 weeks old were used. All manipulations were done in a laminar flow hood. 
All experimental procedures were in complete agreement with the Association for 
Research in Vision and Ophthalmology resolution on the use of animals in research. 
HSV-1 RE, originally provided by the Robert N. Lausch laboratory, was used in all 
procedures. Virus was grown and titrated on Vero cells (American Type Culture 
Collection no. CCL81) using standard protocols. The virus was stored in aliquots at -
80°C until use. 
Abs  
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 CD4-allophycocyanin (RM4.5), CD4-Percp (RM4.5), CD103-allophycocyanin 
(2E7), CTLA-4-PE (UC10-4F10-11), CD45-allophycocyanin (30-F11), CD11b-PerCP 
(M1/70), Ly6G-PE (1A8), CD49d-PE (MFR4.B), CD44-Percp (IM7), and IFN- -
allophycocyanin (XMG1.2) were purchased from BD Biosciences; ICOS-PE (7E.17G9), 
PD1-PE (J43), F4/80-PE (BM8), CD62L-Percp (MEL-14) were purchased from 
eBioscience. 
Corneal HSV-1 infection and clinical observations 
 Corneal infections of C57BL/6 mice were done under deep anesthesia induced by 
intra-peritoneal injection in tribromoethanol (avertin) as previously described (18). 
Corneas were scarified with a 27-gauge needle, and a 3-µl drop containing the specific 
viral dose (2x10
3
 PFU) was applied to the eye. Eyes were examined on different days p.i. 
with a slit-lamp biomicroscope (Kowa Company, Nagoya, Japan) measuring the 
progression of SK lesion severity and angiogenesis of individual mice. The scoring 
system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal 
opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and 
corneal ulcer; +5, corneal rupture and necrotizing keratitis (19). The severity of 
angiogenesis was recorded as described previously (20). According to this system, a 
grade of 4 for a given quadrant of the circle represents a centripetal growth of 1.5 mm 
toward the corneal center. The score of the four quadrants of the eye were then summed 
to derive the neovessel index (range 0–16) for each eye at a given time point. 
Depletion of Treg 
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 To deplete Treg cells, DEREG mice were injected with DT (from 
Corynebacterium diphtheriae, Sigma). Mice were injected intra-peritoneally with 1 g 
DT every other day. Control mice were DEREG mice injected with the vehicle. 
Histopathology 
 Eyes from control and DT-treated mice starting on day 8 p.i. were extirpated on 
day 15 p.i. and snap frozen in OCT compound (Miles, Elkart, IN). Six-micron-thick 
sections were cut and air dried in a desiccation box. Staining was performed with 
hematoxylin and eosin (Richard Allen Scientific, Kalamazoo, MI). 
Flow cytometry 
 Cell preparation. Single cell suspensions were prepared from cornea, cervical 
DLNs, and spleen of mice at different time points p.i. Corneas were excised, pooled 
group wise, and digested with 60 U/ml Liberase (Roche Diagnostics) for 35 min at 37°C 
in a humified atmosphere of 5% CO2. After incubation, the corneas were disrupted by 
grinding with a syringe plunger on a cell strainer, and a single‐ cell suspension was made 
in complete RPMI 1640 medium. 
 Staining for flow cytometry. The single cell suspensions obtained from corneas, 
DLNs, and spleen were stained for different cell surface molecules for FACS. All steps 
were performed at 4°C. A total of 1 X 10
6
 cells were first blocked with an unconjugated 
anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with FACS buffer, 
fluorochrome-labeled respective antibodies were added for 30 min on ice. Finally, the 
cells were washed three times and re‐ suspended in 1% para-formaldehyde. The stained 
samples were acquired with a FACS Calibur (BD Biosciences), and the data were 
analyzed using FlowJo software. For corneas, total cell numbers were calculated by 
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acquiring the totality of the sample and taking into consideration total number of corneas 
in the sample. 
 To enumerate the number of IFN-γ-producing CD4+ T cells, intracellular cytokine 
staining was performed as previously described (21). In brief, 10
6 
freshly isolated 
splenocytes, and lymph node and corneal cells were cultured in U-bottom 96-well plates. 
For in vitro induced cultures, cells were left unstimulated or stimulated with PMA (50 
ng) and ionomycin (500 ng) for 4 h in the presence of brefeldin A (10 µg/ml). 
Subsequently, cell surface staining was performed, followed by intracellular cytokine 
staining using a Cytofix/Cytoperm kit (BD Pharmingen) in accordance with the 
manufacturer’s recommendations. The Abs used were anti-IFN-  allophycocyanin. The 
fixed cells were resuspended in 1% paraformaldehyde. The stained samples were 
acquired with a FACS Calibur (BD biosciences), and the data were analyzed using 
FlowJo software.  For intracellular staining of CTLA-4, we used Foxp3 Staining Buffer 
Set (eBioscience). 
Real-time PCR 
 RNA was extracted from cells and tissue using TRIzol LS reagent (Invitrogen). 
Total cDNA was made with 500 ng of RNA using oligo(dT) primer. Q-RT-PCR was 
performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) 
with an iQ5 RT-PCR detection system (Bio Rad, Hercules, CA) using 5 µl cDNA for 40 
cycles. The expression levels of different molecules were normalized to β-actin using the 
Δ threshold cycle method calculation. Relative expression between mock-infected 
samples and control or day 8 DT-treated samples from day 15 p.i were calculated using 
the 2
-ΔΔCt
 formula: Ct = Ctsample - Ctreference. Here, ΔCt is the change in cycling 
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threshold between the gene of interest and the “housekeeping” gene β-actin, where 
Ctsample was the Ct value for any day 8 DT-treated or control samples from day 15 p.i. 
normalized to the β-actin gene, and Ctreference was the Ct value for the mock-infected 
samples (scratched and infected only with PBS) also normalized to β-actin. Each of the 
samples was run in duplicate to determine sample reproducibility, and a mean Ct value 
for each duplicate measurement was calculated. The PCR primers used were the 
following: actin, F 5’-CCTTCTTGGGTATGGAATCCTG-3’ and R 5’-
GGCATAGAGGTCTTTACGGATG-3’; IL-6, F 5’-
CGTGGAAATGAGAAAAGAGTTGTGC-3’ and R 5’-
ATGCTTAGGCATAACGCACTAGGT-3’; IL-1 , F  5’-
GAAATGCCACCTTTTGACAG-3’ and R 5’- CAAGGCCACAGGTATTTTGT-3’; 
IFN- , F  5’-GGATGCATTCATGAGTATTGC-3’ and R 5’-
GCTTCCTGAGGCTGGATTC-3’; CXCL-9, F 5’-CAAGCCCCAATTGCAACAAA-3’ 
and R 5’- TCCGGATCTAGGCAGGTTTGA-3’; CXCL-10, F 5’-
TGCTGGGTCTGAAGTGGGACT-3’ and R 5’- AAG CTT CCC TAT GGC CCT CA-
3’; MCP-1/CCL2, F 5’-TGGCTCAGCCAGATGCAGT-3’ and R 5’-
TTGGGATCATCTTGCTGGTG-3’; KC/CXCL1, F 5’-GTGTTGCCCTCAGGGCC-3’ 
and R 5’-GCCTCGCGACCATTCTTG-3’. 
ELISA 
 DLN single cell suspensions from individual mice were collected at day 15 p.i. 
Cells were stimulated in vitro with anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml) for 48 h 
at 37°C. Additionally, corneal samples were pooled groupwise (five corneas per sample) 
  53 
and homogenized using a tissue homogenizer (Pellet Pestle mortar; Kontes). For lymph 
node samples, four cervical DNLs were collected for each mouse sample, and ELISA 
was performed on the homogenized sample. The concentrations of IFN-  were measured 
by sandwich ELISA kits from eBioscience as per the manufacturers’ instructions.  
Statistical analysis 
Most of the analyses for determining the level of significance were performed using 
unpaired two‐ tailed Student t tests. Values ***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05 were 
considered significant. Results are expressed as means ± SEM. For some experiments, as 
mentioned in the figure legends, a one-way ANOVA test was applied. 
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Results 
Lymphoid Treg and Th1 response changes after HSV-1 infection 
 Although previous studies reported that local infection with HSV results in 
expansion of the Treg population in infected tissues and the lymphoid sites (22), the 
kinetics of the response was not examined after corneal infection.  As shown in Fig. 1A, 
corneal infection of Foxp3-GFP reporter mice, which express GFP knocked into the locus 
encoding the transcription factor Foxp3 uniquely expressed by Treg (23), caused 
expansion of Treg in the DLN as soon as day 4 p.i. Peak numbers were evident by day 8 
p.i., when the expansion was approximately 4 fold. Numbers of Th1 cells also peaked on 
day 8 p.i.  (Fig.1B). The phenotype of Treg was also measured and compared to 
uninfected controls in the DLN and spleen samples at different time points p.i (day 0, 4, 
8, 12, and 15). As is evident, a greater proportion of Treg from infected animals showed 
increased expression of activation markers, and more were CD103
+
 than uninfected 
controls (Fig. 2A). The expression of other activation markers and costimulatory 
molecules was also altered after infection (Fig. 2B). The frequency of Treg expressing 
CTLA-4 and the ICOS significantly increased in DLN and spleen, peaking on day 15 and 
day 12 p.i., respectively. The expression of the inhibitory receptor PD-1 also changed, 
being downregulated after infection until day 8 p.i and then increasing at later time points 
(day 12 and 15 p.i.) in both organs. Thus, Treg after HSV-1 infection increase in numbers 
in lymphoid tissues and change their surface phenotype to a more increased activation 
phenotype. 
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Treg depletion increases lesion severity 
 To measure the outcome of Treg depletion, DEREG animals (a mouse model in 
which the administration of DT leads to specific depletion of Treg due to expression of 
DT receptor-enhanced GFP under the control of the Foxp3 promoter (24)) were infected 
ocularly with HSV and depletion begun either on day 5, 8, or 12 p.i by administering DT 
and treating every other day after the starting time. All treatment procedures resulted in 
almost total depletion of Treg in the cornea and lymphoid tissues when tested at day 15 
p.i.  (Fig. 3A). Moreover, DT treatment did not affect other lymphocyte subsets (data not 
shown) when started at all three time points. The consequence of Treg depletion was 
significantly increased severity of SK lesions (Fig. 3B and C). Moreover, the average 
time that lesions first became measurable was 1 to 2 days earlier in Treg-depleted 
compared to control animals. The clinical consequence of Treg depletion was greater in 
magnitude the earlier the depletion was commenced, although the differences in outcome 
on day 15 p.i between animals treated on day 5 and day 8 p.i were minimal. On the other 
hand, SK scores from animals that started depletion on day 12 p.i were increased, but 
these changes were not statistically significant. The histological findings in corneas 
showed more severe inflammatory reactions in animals depleted from day 8 p.i compared 
to vehicle-treated controls (Fig. 3D). In conclusion, depletion of Treg during the clinical 
stages of SK resulted in significantly increased lesion severity indicating that Treg play a 
modulating role during the immunopathological process.  
Inflammatory consequences of Treg depletion in the clinical phase of SK 
 In experiments where depletion was commenced on day 8 p.i., pools of corneas 
were collected on day 15 p.i from DT-treated and control animals either to recover 
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inflammatory cells by collagenase digestion or to prepare samples for analysis by Q-RT-
PCR) or protein measurement by ELISA. The numbers of CD45
+
 cells on day 15p.i were 
around 3-fold greater in Treg-depleted animals than controls (Fig. 4A). CD4
+
 T cell 
numbers, too, were around 3-fold greater in Treg-depleted mice when compared to 
controls (Fig. 4B). Additionally, the numbers of neutrophils (CD45
+
CD11b
+
Ly6G
+
) and 
macrophages (CD45
+
CD11b
+
F4/80
+
) were also significantly greater in Treg-depleted 
animals compared to control mice (Fig. 4C and 4D). 
Experiments of the same design were conducted to compare the effector functions 
of infiltrated ocular CD4
+
 T cells in the non-depleted and Treg-depleted DEREG mice. 
The cells isolated from corneal tissues were stimulated with PMA/ionomycin in the 
presence of golgi plug for 4 h. The numbers of Th1 cells were increased around 2-fold in 
the Treg-depleted group compared to control animals (Fig. 4E). The effect of Treg 
depletion on levels of chemokines present in corneas was also measured either by Q-RT-
PCR or proteins by ELISA. As shown in Fig. 5A, samples from depleted animals showed 
increased levels of molecules known from previous studies to participate in the 
pathogenesis of SK (25). These included IL-6 and IL-1β that were increased 5 and 13 
fold respectively. Additionally, significantly increased levels of chemokines involved in 
neutrophil (KC) and monocyte (MCP-1) migration, as well as lymphocyte migration 
(CXCL-9 and CXCL-10), were noted (Fig. 5B). IFN-  protein levels were also increased 
approximately 2 fold in Treg depleted mice (Fig. 5C). 
The increase in CD4
+
 T effector cells in Treg-depleted corneas was attributed to 
an increase in proinflammatory chemokines in the corneas that recruited the 
inflammatory cells. Another possible explanation could be that Treg control the number 
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of effector T cells generated in lymphoid tissues, making fewer available to enter the 
inflamed tissues. To assess this possibility, DLN and spleen cells from day 8 p.i depleted 
and control animals were compared for the number of Th1 cells on day 15 p.i. The results 
shown in Fig. 6A-B demonstrate that Th1 cell total numbers in both DLN and spleen 
were significantly increased in DT recipients when compared to controls. In another set 
of experiments, DLN extracts were collected on day 15 from control and Treg depleted 
mice, and samples analyzed by ELISA for IFN-  protein levels. The data show that Treg 
depletion increased the production of IFN-  by almost 2 fold in the depleted mice (Fig. 
6C). 
Taken together, our results show that Treg depletion during the clinical phase of 
the disease caused a significant increase in the total cellular infiltration of Foxp3
-
 CD4
+
 T 
cells, neutrophils, and macrophages, as well as the amount of proinflammatory cytokines 
and chemokines in the corneas of HSV-1 infected mice. Additionally, effector cell 
numbers and products in lymphoid tissues were increased in the absence of Treg. We 
interpret these data to mean that Treg normally act to modulate the extent of 
inflammatory cell molecule production at the tissue site. The Treg also influence Th1 cell 
numbers and responses in secondary lymphoid tissues, which would reduce the number 
of cells available to infiltrate the inflamed cornea. Additionally, Treg might act to inhibit 
the recruitment of inflammatory cells to the tissue site. Some evidence for this effect is 
described in the next section. 
Consequences of Treg depletion on phenotype of effectors in secondary lymphoid 
tissue  
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 To measure the putative effects of Treg on inflammatory cell recruitment DLN 
cell populations from day 8 p.i., depleted and control animals were compared for surface 
expression of molecules considered as involved in tissue migration. Mice were sacrificed 
2 days after depletion (day 10) and the phenotype of CD4
+
 T cells isolated from DLN and 
spleen evaluated.  The expression of the integrin CD49d (a subunit of VLA 4), a 
molecule known to be involved in the migration of cells to the ocular lesion site (26, 27), 
on Foxp3
-
CD4
+
 lymphocytes was upregulated from 10% (control) to 15% (depleted) in 
DLN and from 18% to 32%, respectively, in the spleen. The number of T effectors 
expressing CD49d was increased 2 fold in DLN and about 2.5 fold in spleen (Fig. 7A). 
FACS analysis also revealed that removal of Treg on day 8 p.i enhanced the expression 
of activation markers on Foxp3
- 
CD4
+
 T cells in DLN and spleen. As shown in Fig. 7B, 
the frequencies of CD4
+
 T cells expressing CD44
hi
 in the DLN and spleen significantly 
increased in the Treg-depleted group compared to controls. Furthermore, around 35% of 
cells in the DLN and 55% in the spleen were CD62L
low
 in the Treg-depleted group 
compared to 28% and 35%, respectively, in control mice (Fig. 7C). The upregulation of 
CD49d on CD4
+
 T cells is likely relevant, since previous studies indicate that blocking 
CD49d reduces SK (26, 27). Our results are consistent with the possibility that Treg 
normally act within lymphoid tissues to reduce the expression of surface molecules such 
as CD49d on activated cells that permit them to migrate to the tissue site. This could 
mean that effector cells could traffic more effectively to tissue sites when not controlled 
by Treg during clinical stages of the disease. 
 
  59 
Discussion 
 Many studies have demonstrated that the extent of inflammatory responses is 
affected by the balance between proinflammatory effectors and events that regulate them, 
such as the activity of Foxp3 Treg cells (11, 13, 28). The conclusion that Treg play a 
modulatory role comes largely from studies that compare the outcome in normal animals 
to that where the Treg composition is manipulated from before or early in the disease 
process. In this investigation, we asked if Treg play an active modulatory role during the 
clinical expression of lesions. This was accomplished by taking advantage of DEREG 
mice where Treg can be successfully and rapidly removed by exposure to DT, which 
depletes the Foxp3+ cells because they express the DT receptor (24, 29). We show, using 
a model in which an inflammatory lesion occurs in the cornea after HSV infection, that 
lesions became more severe even when depletion was begun in the clinical phase of the 
disease. This outcome was explained both by Treg influencing the activity of 
inflammatory effector T cells at the lesion site as well as an effect in lymphoid tissues 
that led to reduced numbers of effectors and less trafficking of T cells and neutrophils to 
the eye.  Our results demonstrate that Treg can beneficially influence the impact of 
ongoing tissue damaging responses to a virus infection and imply that therapies that boost 
Treg function in the clinical phase hold promise as a modality to control a lesion that is 
an important cause of human blindness. 
 Since the milestone report from Belkaid and colleagues (30), we have known that 
Treg are induced by infections and that they play a significant role in shaping the pattern 
of disease responses. Treg for instance are considered to influence the outcome of 
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persistent infections as they similarly do in autoimmune diseases (13, 15). However, the 
majority of studies that implicate Treg during an infectious disease either compared the 
outcome of disease in animals depleted of Treg from the onset with controls, or observed 
the consequence of boosting Treg responses early or before infection (11, 31, 32). In our 
study, we attempted to evaluate the function of Treg during an ongoing inflammatory 
process by removing them when clinical lesions are already present. This was shown by 
exploiting the transgenic mouse system developed by Sparwasser and colleagues (29) 
that permits rapid and almost total selective elimination of Foxp3
+
 Treg at any stage in 
the disease process. Our results clearly show that removing Treg in the clinical phase of 
the disease resulted in lesions becoming more severe. This could be demonstrated not 
only clinically, but also by comparing the number of inflammatory cells and their 
products in the corneas of Treg-depleted with control animals. In the absence of Treg, 
greater numbers of the effector T cells that orchestrate lesions were present, as well as 
non-lymphoid inflammatory cells such as neutrophils, the latter mainly responsible for 
damage to the corneal stroma (33, 34). Although our results demonstrate that without 
Treg, lesions became more severe, we provide no direct evidence that the Treg subserve 
their function only at the tissue site. 
 The problem with attempts to conclude that Treg exert functional effects solely 
within inflammatory reactions is that the depletion procedure also had proinflammatory 
consequences in lymphoid tissues. Accordingly, effector cell numbers were increased by 
Treg ablation, and the average phenotype of CD4
+
 T cells involved in orchestrating SK 
lesions showed changes. These included increased numbers of cells with an activation 
phenotype and increased cell numbers that expressed molecules shown in previous 
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studies to be required for migration to the corneal tissue site (26). Consequently, it 
remains possible that the major influence of Treg during the infection occurs by the DLN 
acting to limit the number of activated T effectors and the generation of inflammatory 
cells that express receptors that permit their passage to tissue sites. Further experiments 
are needed to define the relative importance of tissue acting versus lymphoid organ 
effects of Treg on the inflammatory response. However, as reviewed by Shevach (35), 
Treg suppress immune responses at multiple levels with different mechanisms of action 
in different experimental models.  
 Our observation adds further evidence to the notion that Treg can play a critical role 
during responses to infections and implies that amplifying their function in the phase of 
active lesions would likely be beneficial to the outcome. This may be especially relevant 
in situations such as SK where replicating virus is minimal or absent at the phase of the 
inflammatory response (25). However, it remains to be shown how the latter effect can be 
most effectively achieved particularly if, as has been advocated (36), the Treg that 
function most effectively need to be antigen specific. In the case of the virus-induced 
immunopathology caused by HSV ocular infection, Treg may not need to be virus-
specific as long as they express the activation and migration phenotypes that permit them 
to access the site of inflammation (12). Whereas antigen specificity may facilitate the 
regulatory activity of Treg, it is also conceivable that as long as the Treg are activated 
and can successfully gain entrance into inflammatory sites, Treg of multiple specificities 
could still subserve a useful function. This is to be expected, especially when Treg 
function by producing soluble anti-inflammatory mediators such as IL-10 and TGF- , 
and IL35 (35, 36, 37). In addition, in past studies we have shown that the adoptive 
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transfer of Foxp3
+
 Treg reactive with OVA peptide, can readily enter the inflamed cornea 
(12). Moreover, there is some evidence that SK lesions may be in part autoreactive (38), 
meaning that self-reactive Treg, a major fraction of the Foxp3
+
 Treg population (13, 36), 
could participate in regulatory lesion severity. 
 Our study shows that Treg function is needed to limit the extent of virus-induced 
inflammatory lesions, and implies that expanding and activating Treg could be 
therapeutically valuable. Moreover, if, as we advocate, Treg do not need to share antigen 
reactivity with the proinflammatory effectors they regulate, approaches that expand Treg 
polyclonally are more available than are maneuvers to expand Ag-specific Treg. Of the 
polyclonal approaches reported, the ones described by Sprent et al (39, 40) and Podack 
and colleagues (41, 42) have particular appeal.  Podack’s approach exploits the fact that 
among naïve and resting T cells, the monoclonal antibody for the TNF receptor 25 
(mAbT25) is expressed predominantly on Foxp3
+
 Treg (41). Moreover, if the receptor is 
engaged with an agonistic monoclonal antibody, the Treg population is preferentially 
expanded and activated. We have found this approach to be effective to expand Treg and 
diminish SK lesions (42). However, the downside of using mAbT25 is that activated 
effectors also express TNFR25 and may also be expanded, which could lead to and cause 
exacerbated tissue damage. Fortunately, this problem can be overcome by the co-
administration of additional therapies that selectively cause apoptosis of effectors (42). 
 In conclusion, our results indicate that Treg play a beneficial role to minimize and 
modulate the severity of SK lesions during the clinical phase. Our results imply that 
therapies that boost Treg function in the clinical phase hold promise as a modality to 
control a lesion that is an important cause of human blindness. 
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FIGURE 2.1. Lymphoid Treg and Th1 response changes after HSV-1 
infection.  
Foxp3
-
GFP mice corneas were scarified and infected with HSV-1, and flow cytometry 
was used to quantify Treg and Th1 cells in DLN and spleen of naïve and infected mice at 
different times after corneal infection with HSV-1. (A) Representative frequencies and 
numbers of Treg in DLN and spleen of infected mice at different time points. (B) 
Representative frequencies and numbers of Th1 cells in DLN and spleen of infected mice 
at different times. Data are representative of three independent experiments and show 
mean values ± SEM (n = 6 mice at each indicated time point p.i.). ***p ≤ 0.001,**p ≤ 
0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by one-way ANOVA test 
with Dunnett’s post hoc test settings.  
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FIGURE 2.2. HSV-1 infection changes Treg cell surface phenotype.  
 Foxp3-GFP mice corneas were scarified and infected with HSV-1. (A) Flow cytometry 
was used to detect CD103 expression on Treg. Cells from DLN and spleen of naïve (day 
0) and HSV-1-infected mice at different time points were stained for CD4 and CD103. 
Histograms were gated on CD4
+
Foxp3
-
GFP
+ 
cells. The frequencies of Treg expressing 
CD103 are shown. (B) Flow cytometry was used to detect different surface markers on 
Treg: CTLA-4, ICOS, and PD-1. Cells from DLN and spleen of naïve (day 0) and HSV-
1-infected mice at different time points were stained for CD4, CTLA-4, ICOS, and PD-1. 
Histograms are gated on CD4
+
Foxp3-GFP
+
 cells. The frequencies of Treg expressing 
CTLA-4, ICOS, and PD-1 are shown. Data are representative of three independent 
experiments and show mean values ± SEM (n = 6 mice at each indicated time point p.i.). 
***p ≤ 0.001,**p ≤ 0.01(),*p ≤ 0.05. Statistical levels of significance were analyzed by 
one-way ANOVA test with Dunnett’s post hoc test settings. 
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FIGURE 2.3. Depletion of Treg during clinical stages of disease 
increases SK lesion severity.  
DEREG mice infected with HSV-1 were given either DT or vehicle IP starting on day 5 
or 8 or 12 p.i., and treated every other day until the termination day (day 15 p.i.). (A) 
Starting on day 8 p.i. mice were treated either with DT (1μg/day) or vehicle every other 
day, mice were sacrificed on day 15 p.i., and lymphoid organs were removed. Flow 
cytometry analysis of lymphoid cells from cornea, DLN, and spleen show efficient 
depletion of Treg in DT-treated DEREG mice compared with DT PBS-treated DEREG 
mice. (B) The progression of SK lesion severity was significantly increased in the group 
of mice treated with DT as compared with control mice. Kinetics of SK lesion severity 
are shown. Individual eye scores of SK lesion severity on day 15 p.i. are shown. SK 
lesion severity was significantly increased in the groups of mice treated with DT starting 
on day 5 and 8 p.i. as compared with control mice. (C) Representative eye photos show 
increased SK lesion severity, as well as angiogenesis, from DT-treated mice starting on 
day 8 p.i. compared with vehicle-treated mice. (D) Eyes were processed for cryo-sections 
on day 15 p.i. Hematoxylin and eosin staining was carried out on 6-μm sections, and 
pictures were taken at different microscope augmentations (20X and 40X magnification). 
Representative eye sections show increased cellular infiltration in DT-treated mice 
starting on day 8 p.i. when compared to vehicle-treated animals. Data are representative 
of three independent experiments and show mean values ± SEM (n = 12-15 mice/group). 
***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by the 
Student t test (unpaired).  
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FIGURE 2.4. Depletion of Treg increases cellular infiltration in corneas 
of HSV-1-infected animals.   
DEREG mice infected with HSV-1 were given either DT or vehicle IP starting on day 8 
p.i. every other day until the termination day (day 15 p.i.). (A) Representative FACS 
plots, and frequencies and numbers of CD45
+
 cells infiltrated in the corneas of control 
and DT-treated mice are shown. (B) Representative FACS plots, and frequencies and 
numbers of CD4
+
 T cells infiltrated in the corneas of control and DT-treated mice. (C) 
Representative FACS plots, and frequencies and numbers of CD11b
+ 
Ly6G
+ 
polymorphonuclear neutrophils gated on total CD45
+
 cells infiltrated in the corneas of 
control and DT-treated mice are shown. (D) Representative FACS plots, and frequencies 
and numbers of CD11b
+
 F4/80
+
 (macrophages) gated on total CD45
+
 cells infiltrated in 
the corneas of control and DT-treated mice are shown. (E) Representative FACS plots, 
and frequencies and numbers of IFN-γ-secreting cells gated on CD4+ T cells infiltrated in 
the cornea on day 15 p.i. and stimulated with PMA/ionomycin for 4 h from control and 
DT-treated mice. Data are representative of three independent experiments and show 
mean values ± SEM (n = 10-12 mice/group, each sample is representative of  2 corneas). 
***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by the 
Student t test (unpaired). 
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FIGURE 2.5. Depletion of Treg increases cytokine and chemokine levels 
in corneas of HSV-1-infected animals.   
DEREG mice infected with HSV-1 were given either DT or vehicle i.p. starting on day 8 
p.i. every other day until the termination day (day 15 p.i.). Mice were sacrificed on day 
15 p.i., and corneal extracts were collected for measuring inflammatory factors using 
either Q-RT-PCR or sandwich ELISA. (A) Relative fold change in mRNA expression of 
the proinflammatory cytokines IL-1β and IL-6 was examined and compared between 
control and DT-treated mice on day 15 p.i. by Q-RT-PCR. (B) Relative fold change in 
mRNA expression of the chemokines KC, MCP-1, CXCL9, and CXCL10 was examined 
and compared between control and DT-treated mice on day 15 p.i. by Q-RT-PCR. mRNA 
levels for the different cytokines in mock-infected mice were set to one and used for the 
relative fold upregulation. (C) IFN-  protein levels from pooled corneal samples from 
control and DT-treated animals were quantified using ELISA. Data are representative of 
three independent experiments and show mean values ± SEM (n = 12 mice/group, each 
sample is representative of 4 corneas). ***p ≤ 0.001,**P ≤ 0.01,*P ≤ 0.05. Statistical 
levels of significance were analyzed by the Student t test (unpaired). 
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FIGURE 2.6. Treg depletion increases Th1 responses and cell numbers 
in response to HSV-1 infection.  
DEREG mice infected with HSV-1 were given either DT or vehicle i.p. starting on day 8 
p.i. every other day until the termination day (day 15 p.i.). (A) Representative FACS 
plots, and frequencies and numbers of IFN-γ-secreting cells gated on CD4+ T cells 
infiltrated in DLN on day 15 p.i. and stimulated with PMA/ionomycin for 4 h from 
control and DT-treated mice. (B) Representative FACS plots, and frequencies and 
numbers of IFN-γ-secreting CD4+ T cells from spleen on day 15 p.i. from control and 
DT-treated mice. (C) IFN-γ protein levels analyzed by ELISA from control and DT-
treated DLN and spleen on day 15p.i. Data are representative of three independent 
experiments and show mean values ± SEM (n = 10-12 mice/group). ***p ≤ 0.001,**p ≤ 
0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by the Student t test 
(unpaired). 
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FIGURE 2.7. Treg depletion during the clinical phase of SK causes 
phenotype changes in secondary lymphoid tissue effectors.   
DEREG mice infected with HSV-1 were given either DT or vehicle IP starting on day 8 
p.i. every other day until the termination day (day 10 p.i.). (A) Representative FACS 
plots, and frequencies and numbers of CD4
+
CD49d
+
 T cells in DLN and spleen of control 
and DT-treated mice are shown. (B) Representative histogram plots and frequencies of 
CD4
+
CD44
hi
 T cells in DLN and spleen of control (gray) and DT-treated (thick line) mice 
are shown. (C) Representative histogram plots and frequencies of CD4
+
CD62L
low
 T cells 
in DLN and spleen of control (gray) and DT-treated (thick line) mice are shown. Data are 
representative of three independent experiments and show mean values ± SEM (n = 10-
12 mice/group). ***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of significance were 
analyzed by the Student t test (unpaired). 
 
 
 
 
 
 
 
 
 
 
  83 
 
 
 
 
  84 
 
CHAPTER II 
CONTROLLING VIRAL 
IMMUNOINFLAMMATORY LESIONS BY 
MODULATING ARYL HYDROCARBON 
RECEPTOR SIGNALING 
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Research described in this chapter is a slightly modified version of an article published in 
PLoS Pathogens by Tamara Veiga Parga, Amol Suryawanshi and Barry T Rouse. 
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Lesions by Modulating Aryl Hydrocarbon Receptor Signaling PLoS Pathog. 2011. 7(12). 
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Abstract 
Ocular herpes simplex virus infection can cause a blinding CD4
+
 T cell 
orchestrated immunoinflammatory lesion in the cornea called Stromal Keratitis (SK). A 
key to controlling the severity of SK lesions is to suppress the activity of T cells that 
orchestrate lesions and enhance the representation of regulatory cells that inhibit effector 
cell function. In this report we show that a single administration of TCDD (2, 3, 7, 8- 
Tetrachlorodibenzo-p-dioxin), a non-physiological ligand for the AhR receptor, was an 
effective means of reducing the severity of SK lesions. It acted by causing apoptosis of 
Foxp3
-
 CD4
+
 T cells but had no effect on Foxp3
+
 CD4
+
 Tregs. TCDD also decreased the 
proliferation of Foxp3
-
 CD4
+
 T cells. The consequence was an increase in the ratio of 
Tregs to T effectors which likely accounting for the reduced inflammatory responses. In 
addition, in vitro studies revealed that TCDD addition to anti-CD3/CD28 stimulated 
naïve CD4
+ 
T cells caused a significant induction of Tregs, but inhibited the 
differentiation of Th1 and Th17 cells. Since a single TCDD administration given after the 
disease process had been initiated generated long lasting anti-inflammatory effects, the 
approach holds promise as a therapeutic means of controlling virus induced inflammatory 
lesions. 
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Introduction 
          Ocular infection with herpes simplex virus (HSV) can result in a chronic 
immunoinflammatory reaction in the cornea, which represents a common cause of human 
blindness [1,2]. The pathogenesis of stromal keratitis (SK) involves numerous events, but 
studies in murine SK models indicate that lesions are mainly orchestrated by CD4
+
 T 
cells that recognize virus derived peptides, or perhaps altered self-proteins unmasked in 
the damaged cornea [1,2,3,4]. The severity of SK can be influenced by the balance of 
CD4
+
 effector T cells and Foxp3
+
 regulatory T cells (Treg) [5,6]. Procedures that change 
this balance represent a promising approach for therapy. This has been achieved either by 
adoptive transfer with Treg populations [6] or the repeated administration of reagents that 
can cause naïve CD4
+
 T cells to convert to become Treg [7,8]. From a therapeutic angle, 
procedures that could shift the balance of T effectors and Treg after a single drug 
administration would represent a convenient maneuver.  
Recent evidence from studies to control autoimmunity and graft-versus-host 
disease indicate that the objective might be achieved by the administration of stable 
agonists of the aryl hydrocarbon receptor (AhR) [9,10,11]. The AhR is a cytosolic 
transcription factor that can be activated by different ligands. These include the 
physiological ligand tryptophan photoproduct 6-formylindolo (2,3-b) carbazole (FICZ), 
and synthetic molecules such as 2, 3, 7, 8- tetrachlorodibenzo-p-dioxin (TCDD) [10,12]. 
Signaling through the AhR has consequences that include changes in innate cell function, 
as well as some modulatory effects on several aspects of T cell immunity [13,14]. For 
example, Weiner and colleagues showed that TCDD administration could suppress the 
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induction of experimental autoimmune encephalomyelitis (EAE), an effect attributed to a 
reduction of proinflammatory T cells along with the expansion of Treg [9]. By a similar 
mechanism, TCDD had suppressive effects in an autoimmune diabetes model [15]. 
Similarly, the administration of TCDD prior to the induction of colitis led to reduce 
lesions along with an increase in the Treg population [16]. In graft versus host disease 
(GVHD) too the reduced lesions in TCDD treated animals was attributed to the 
expansion of adaptive Tregs that suppressed allospecific cytotoxic T cell generation 
[11,17]. Modulating AhR by TCDD has also been shown to control the differentiation of 
Type 1 regulatory T cells (Tr1) cells in vitro, which produce IL-10 and are instrumental 
in the prevention of tissue inflammation, autoimmunity as well as GVHD [18]. 
Although AhR ligation can result in reduced inflammatory lesions, in some 
circumstances lesions may be exacerbated. This was noted in the Weiner studies when 
the physiological ligand FICZ, rather than TCDD, was used for treatment [9]. In this 
study administration of FICZ boosted Th17 differentiation and increased the severity of 
EAE. Proinflammatory effects of AhR activation were also noted in a model of 
rheumatoid arthritis [19], where synoviocytes were exposed to different concentrations of 
TCDD and shown to produce inflammatory cytokines.   Additional proinflammatory 
effects of AhR ligation were also associated with pulmonary neutrophilia [20,21], as well 
as with the induction and expansion of IL-17
+
 secreting CD4
+
 T cells (Th17) that 
expressed high levels of AhR receptors [22,23]. Currently, it is not clear why AhR 
activation causes either an increased, or a reduced effect on inflammatory reactions, but 
the stability of the ligand used for AhR stimulation is one suspected explanation [24]. 
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Accordingly, TCDD is a non-degradable high affinity ligand for AhR and most studies 
using this ligand report inhibitory effects on inflammatory reactions [24,25] . 
The effects of AhR agonists have not been evaluated in microbe induced 
inflammatory lesions. In this report, we show that a single administration of the stable 
AhR ligand TCDD was highly effective at suppressing the severity of ocular 
immunoinflammatory lesions caused by HSV. The outcome was attributed to inhibitory 
effects on inflammatory IFN-γ+ secreting CD4+ T cells (Th1) and Th17 cells. However, 
since Foxp3
+
 regulatory T cell numbers remained unchanged by the treatment, the 
balance between T effectors and Tregs favored the latter population. TCDD was also 
shown to cause apoptosis ex vivo of Foxp3
-
 CD4
+
 T cells and could cause some naïve T 
cells to convert to Foxp3
+
 CD4
+
 T cells. Since a single TCDD administration given after 
the disease process had been initiated generated long lasting anti-inflammatory effects, 
the approach holds promise as a therapeutic means of controlling virus induced 
inflammatory lesions. 
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Materials and Methods 
Ethics Statement 
 This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Research Council. All 
animals were housed in Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC)-approved animal facilities. The protocol was approved by the 
Institutional Animal Care and Use Committee of the University of Tennessee (PHS 
Assurance number A3668-01). HSV-1 eye infection was performed under anesthesia 
(avertin), and all efforts were made to minimize animal suffering. 
Mice, virus and cell lines 
 Female 6 to 8 weeks old C57BL/6 mice were purchased from Harlan Sprague 
Dawley (Indianapolis, IN). BALB/c DO11.10 RAG2 
-/-
 mice were purchased from 
Taconic and kept in our pathogen free facility where food, water, bedding, and 
instruments were autoclaved. All manipulations were done in a laminar flow hood. All 
experiment procedures were in complete agreement with the Association for Research in 
Vision and Ophthalmology resolution on the use of animals in research. HSV-1 RE 
Tumpey and HSV-RE Hendricks were propagated and titrated on Vero cells (American 
Type Culture Collectin no. CCL81) using standard protocols. The virus was stored in 
aliquots at -80ºC until use. 
Abs  
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 CD4-allophycocyanin (RM4.5), CD4-FITC (RM4.5), Foxp3-PE (FJK-16s), anti-
IFN- -FITC (XMG1.2), anti-IL17-PE (TC11-18H10), CD45-allophycocyanin (30-F11), 
CD11b-PerCP (M1/79), Ly6G-PE (1A8). 
Corneal HSV-1 infection and clinical observations 
 Corneal infections of C57BL/6 mice were done under deep anesthesia induced by 
I.P injection in tribromoethanol (avertin) as previously described [48]. Mice’s corneas 
were scarified with a 27-gauge needle, and a 3 µl drop containing the specific viral dose 
was applied to the eye. Eyes were examined on different days post infection (dpi) with a 
silt-lamp biomicroscope (Kowa Company, Nagoya, Japan) measuring the progression of 
SK lesion severity and angiogenesis of individual mice. The scoring system was as 
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or 
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer; 
+5, corneal rupture and necrotizing keratitis [49]. The severity of angiogenesis was 
recorded as described previously [50]. According to this system, a grade of 4 for a given 
quadrant of the circle represents a centripetal growth of 1.5 mm toward the corneal 
center. The score of the four quadrants of the eye were then summed to derive the 
neovessel index (range 0–16) for each eye at a given time point. 
Treatment of animals with TCDD 
 TCDD (Sigma Aldrich) diluent was evaporated with nitrogen and reconstituted 
with DMSO. Female 6 to 8 weeks old C57BL/C mice were ocularly infected under deep 
anesthesia with 1X 10
4 
PFU of HSV-1 RE Tumpey and divided randomly into groups. 
Animals in the treated groups were either treated with TCDD on day 1 pi or day 5pi 
intraperitoneally (IP), being the dose administered of 1µg/mice. Animals in the control 
  92 
groups were treated the same days (either day 1 or day 5 p.i) with DMSO IP.  Mice were 
observed for HSK and angiogenesis progression from day 5 until day 15 or 28 as 
described elsewhere [49]. Most of the experiments were repeated at least three times. 
Treatment of animals with FICZ 
 FICZ (Biomol International, L.P., Plymouth Meeting, PA) was dissolved in 
DMSO. Female 6 to 8 weeks old C57BL/C mice were ocularly infected under deep 
anesthesia with 1X 10
4
 PFU of HSV-1 RE Tumpey and divided randomly into groups. 
Animals in the treated groups were either treated daily with FICZ from day 1 pi to day 11 
pi (IP), being the dose administered of 1µg/mice. Animals in the control groups were 
treated the same days with DMSO IP.  Mice were observed for HSK and angiogenesis 
progression from day 5 until day 15 as described elsewhere [49].  
Virus recovery and titrations 
 Eye swabs were taken from infected corneas using sterile swabs at the indicated 
time points. Infected corneas were extracted on day 6 pi and placed on ice sterile 2.0-mL 
straight-wall ground-glass tissue homogenizers (Wheaton) with media and homogenized. 
Homogenates were centrifuged (2,250 g at 4°C) for 5 min, place on ice, and immediately 
plated. Titrations were performed by a standard plaque assay as described previously 
[51]. Titers were calculated as log10 pfu/ml per a standard protocol [52]. 
Histopathology 
 Eyes from control and TCDD treated mice were extirpated on day 15 pi and snap 
frozen in OCT compound (Miles, Elkart, IN). Six micron thick sections were cut, air 
dried in a desiccation box. Staining was performed with hematoxylin and eosin (Richard 
Allen Scientific, Kalamazoo, MI). 
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Flow Cytometry 
 Cell preparation. Single cell suspensions were prepared from cornea, draining 
cervical limph nodes (DLN), and spleen of mice at different time points postinfection. 
Corneas were excised, pooled group wise, and digested with 60 U/ml Liberase (Roche 
Diagnostics) for 35 minutes at 37
o
C in a humified atmosphere of 5% CO2. After 
incubation, the corneas were disrupted by grinding with a syringe plunger on a cell 
strainer and a single cell suspension was made in complete RPMI 1640 medium. 
Staining for flow cytometry. The single cell suspensions obtained from corneas, DLN, 
and spleens were stained for different cell surface molecules for FACS. All steps were 
performed at 4
o
C. A total of 1 X 10
6
 cells were first blocked with an unconjugated 
anti‐ CD32/CD16 mAb for 30 min in FACS buffer. After washing with FACS buffer, 
fluorochrome-labeled respective antibodies were added for 30 min on ice. Finally, the 
cells were washed three times and re‐ suspended in 1% para‐ formaldehyde. The stained 
samples were acquired with a FACS Calibur (BD Biosciences) and the data were 
analyzed using the FlowJo software. For corneas, total cell numbers were calculated by 
acquiring the totality of the sample and taking in consideration total number of corneas in 
the sample. 
 To enumerate the number of IFN-γ and IL-17 producing CD4+ T cells, 
intracellular cytokine staining was performed as previously described [5]. In brief, 10
6 
freshly isolated splenocytes, lymph node and corneal cells were cultured in U bottom 96 
well plates. For in vitro induced cultures, cells were left unstimulated or stimulated with 
PMA (50ng) and ionomycin (500ng) for 4h in the presence of brefeldin A (10µg/ml). 
Subsequently, cell surface staining was performed, followed by intracellular cytokine 
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staining using a Cytofix/Cytoperm kit (BD Pharmingen) in accordance with the 
manufacturer’s recommendations. The Abs used were anti-IFN-  FITC and anti-IL-17 
PE. The fixed cells were resuspended in 1% paraformaldehyde. The stained samples were 
acquired with a FACS Calibur (BD biosciences), and the data were analyzed using the 
FlowJo software. 
Real time PCR 
 RNA was extracted from cells and tissue using TRIzol LS reagent (Invitrogen). 
Total cDNA was made with 500ng of RNA using oligo(dT) primer. Quantitative PCR 
(Q-RTPCR) was performed using SYBR Green PCR Master Mix (Applied Biosystem, 
Foster City, CA) with iQ5 real-time PCR detection system (Bio Rad, Hercules, CA) using 
5µl of cDNA for 40 cycles. The expression levels of different molecules were normalized 
to β-actin using Δ threshold cycle method calculation. Relative expression between mock 
infected samples and control or day 5 TCDD treated samples from day 15 pi were 
calculated using the 2
-ΔΔCt
 formula: Ct = Ct,sample - Ct,reference. Here, ΔCt is the 
change in cycling threshold between the gene of interest and the 'housekeeping' gene β-
actin, where Ct,sample was the Ct value for any day 5 TCDD treated or control samples 
from  day 15 pi  normalized to the β-actin gene and Ct,reference was the Ct value for the 
mock infected samples (scratched and infected only with PBS) also normalized to β-
actin. Each of the samples was run in duplicates to determine sample reproducibility, and 
a mean Ct value for each duplicate measurement was calculated. The PCR primers used 
were the following: -actin F 5’-CCTTCTTGGGTATGGAATCCTG-3’ and R 5’-
GGCATAGAGGTCTTTACGGATG-3’,IL-6 F 5’-
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CGTGGAAATGAGAAAAGAGTTGTGC-3’ and R 5’- 
ATGCTTAGGCATAACGCACTAGGT-3’, TNF-α  F 5’-
CAGCCTCTTCTCATTCCTGCTTGTG-3’ and R 5’- 
CTGGAAGACTCCTCCCAGGTATAT-3’,IL-1  F  5’-
GAAATGCCACCTTTTGACAG-3’ and R 5’- CAAGGCCACAGGTATTTTGT-3’,IFN-
 F  5’-GGATGCATTCATGAGTATTGC-3’ and R 5’- GCTTCCTGAGGCTGGATTC-
3’,IL-17A F  5’-GCTCCAGAAGGCCCTCAG-3’ and R 5’- 
CTTTCCCTCCGCATTGACA-3’,IL-10 F  5’- CCTTTGACAAGCGGACTCTC-3’ and 
R 5’- GCCAGCATAAAAACCCTTCA-3’,CXCL-9 F 5’-
CAAGCCCCAATTGCAACAAA-3’ and R 5’- TCC GGA TCT AGG CAG GTT TGA-
3’,CXCL-10 F 5’-TGC TGG GTC TGA AGT GGG ACT-3’ and R 5’- AAG CTT CCC 
TAT GGC CCT CA-3’,CXCL-11 F 5’-GGTCACAGCCATAGCCCTG-3’ and R 5’- 
AGCCTTCATAGTAACAATC-3’, CCL-20 F 5’-GCCTCTCGTACATACAGACGC-3’ 
and R 5’-  CCAGTTCTGCTTTGGATCAGC-3’ 
Purification of CD4
+
 T cells 
 CD4
+ 
T cells were purified from pooled DLN single cell suspension obtained 
from HSV-infected mice using a mouse CD4
+
 T cell isolation kit (Miltenyi Biotec, 
Auburn, CA). The purity was achieved at the extent of 90%. Purified CD4
+ 
T cells were 
analyzed by Flow cytometry and ELISA after stimulation for the expression of IFN-  and 
IL-17. 
ELISA 
 DLN single cell suspensions from individual mice were collected at day 15 pi. 
Cells were stimulated in vitro with anti-CD3 (2µg/ml) and anti-CD28 (1µg/ml) for 48 h 
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at 37
o
C. Additionally DLN single cell suspensions from mice were also collected at day 
10 pi and CD4
+
 T cells were purified using magnetic columns. Cells were then stimulated 
in vitro with PMA (50ng) and ionomycin (500ng) for 4 h at 37
o
C. The concentrations of 
IFN-  and IL-17 were measured by sandwich ELISA kits from eBioscience.  
In vitro induction of CD4
+
CD25
+
Foxp3
+
 regulatory T cells 
 Splenocytes isolated from DO11.10 RAG2 
-/-
 mice were used as a precursor 
population for the induction of Foxp3
+
 in CD4
+
 T cells as described elsewhere [6]. 
Briefly, 2 X 10
6
 splenocytes after RBC lysis and several washings were cultured in 1ml 
volume previously optimized doses of plate bound anti-CD3 Ab (0.123 µg/ml in 200 µl 
total volume), rIL-2 (25-100U/ml) and TGF  (2.5-10ng/ml) for 5days at 37ºC in a 5% 
CO2 incubator. Different concentrations of TCDD were also added. After 5 days samples 
were characterized for Foxp3 intranuclear staining using an eBioscience kit and analyzed 
by flow cytometry. 
Th1 and Th17 differentiation in vitro 
 Naïve CD4
+
 T cells were stimulated for 4 to 5 days with plate bound antibody to 
CD3 (4µg/ml) and anti CD28 (2µg/ml). For Th1 differentiation recombinant mouse IL-12 
(10ng/ml) and anti IL-4 (10µg/ml) were used. In the case of Th17 differentiation TGF-  
(2.5ng/ml), IL-6 (30ng/ml), anti IL-4 (10µg/ml) and anti IFN-γ (10µg/ml) were added. 
Concentrations of TCDD were added into cultures at the beginning of the experiment. 
After 5 days samples were analyzed by intracellular cytokine staining for the production 
of IFN-  and IL-17 using a BD biosciences kit and then flow cytometry. 
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The culture mediums used were IMDM (Sigma-Aldrich) for Th17 differentiation or 
RPMI 1640 (Sigma-Aldrich) for Th1 differentiation, both supplemented with 2 × 10
−3
 M 
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 5 × 10
−5
 M β-
mercaptoethanol, and 5% FCS [53].  
BrdU incorporation assay 
 Foxp3
+
-GFP knock-in animals were kindly provided by Dr. M. Oukka of Seattle 
Children’s Research Institute. Mice were infected and divided into two groups: 
nontreated and TCDD treated mice. 8 days after ocular HSV 1 infection mice were 
injected IP with BrdU (1mg/mouse) and were terminated 12 hours later. 9 days post 
infection, host Foxp3
+
CD4
+
 and Foxp3
-
CD4
+ 
T cells that incorporated BrdU were 
analyzed by staining with anti BrdU antibody using an APC BrdU flow kit from BD 
Pharmingen as per the manufacturer’s instructions. Samples were acquired with a 
FACSCalibur (BD biosciences), and the data were analyzed using the FlowJo software. 
Ex vivo apoptosis assay 
 DLN cells and splenocytes isolated from HSV-infected Foxp3-GFP C57BL/6 
mice at 8 days pi were incubated for 5h with various concentrations of TCDD in 96 well 
flat-bottom plate in 5% CO2 incubators. After incubation period was over, cells were 
stained for annexin V using a kit from BD biosciences. Additionally cells were co-stained 
for CD4.  Stained cells were analyzed immediately by flow cytometry. 
Statistical analysis 
 Most of the analyses for determining the level of significance were performed 
using unpaired two-tailed Student’s t test. Values P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 
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0.05(*) were considered significant. Results are expressed as means ±SEM. For some 
experiments, as mentioned in the figure legends, a one-way ANOVA test was applied. 
 
Results 
Modulation of AhR signaling diminishes HSV-1 mediated immunopathology 
To evaluate the role of AhR engagement on the outcome of ocular HSV infection, 
mice were given a single intraperitoneal (IP) administration of TCDD on day 1 pi, and 
the effect on the severity of ocular lesions was compared to untreated controls. All treated 
animals developed significantly reduced lesions compared to controls, but around 40% of 
the animals developed clinical signs typical of herpes encephalitis before the end of the 
15 day observation period and had to be terminated (Fig. 1A-D). Ocular viral loads were 
also increased in the TCDD treated group (Fig. 1E). Accordingly, the drug was judged to 
be effective but would not be recommended for use when virus is present and actively 
replicating in the cornea. In other experiments, the physiological AhR ligand FICZ was 
administered daily starting at day 1 pi. This drug was without significant effects on lesion 
severity (Fig. 1F), and none of the treated animals developed herpetic encephalitis (data 
not shown). 
In additional experiments, TCDD administration was begun on day 5, a time when 
levels of replicating virus in the cornea were barely detectable and inflammatory lesions 
start to become evident [3]. This treatment procedure resulted in significantly reduced 
lesion severity, as well as the extent of corneal neovascularization, compared to untreated 
infected controls (Fig. 2 A-D), and none of the treated animals developed encephalitis. 
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The treatment procedure delayed the time of lesion appearance and average severity 
scores were significantly less at most time points over a 15 day observation period. For 
example, on day 12 pi, whereas 10 of 12 eyes from untreated animals had lesion scores of 
3 or above, only 2 of 14 eyes in the treated group had lesions of such severity (Fig. 2B). 
An example of comparative severity of control and treated animals is shown in the 
histological sections in figure 2E. In additional experiments terminated on day 28 pi, the 
pattern of results was similar with treated animals showing significantly diminished 
lesions compared to untreated controls (Fig. 2F). In conclusion, ligation of the AhR with 
a single administration of TCDD given 5 days after virus infection significantly 
diminished HSV induced immunopathology. 
 
Modulation of AhR signaling diminishes cell infiltration as well as cytokines after 
HSV-1 infection 
To measure the effect of TCDD treatment on the cellular composition of SK 
lesions collagen digested corneas were analyzed by FACS and compared to controls at 
day 15 pi. The combination of three independent experiments is shown in figure 3A-D. 
As shown in figure 3D, the average number per cornea of neutrophils and CD4
+
 T cells 
was reduced in the treated group by 2.03 fold and 4.7 fold respectively when compared to 
untreated controls. 
In separate experiments of the same design, pools of corneas were processed to 
quantify mRNA of selected cytokines (IL-1β, TNF-α, IL-6, IFN-γ, and IL-17) and 
chemokines (CCL20, CXCL9, 10, 11) by quantitative real time PCR (Q-RTPCR). As 
shown in figure 3C, the consequence of TCDD treatment was a reduction in the levels of 
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several proinflammatory cytokines and chemokines. However, levels of the cytokine IL-
10 was increased to 1.4 fold in samples from treated compared to controls. Taken 
together, our results show AhR ligation by TCDD significantly reduced the total cellular 
infiltration of CD4
+
 T cells and neutrophils, as well as the amount of proinflammatory 
cytokines and chemokines. 
 
AhR signaling changes the balance of effectors and T reg  
To measure the consequences of TCDD treatment on the T cell subset 
composition of SK lesions at day 15 pi, pools of corneas from treated and control animals 
were collagen digested to recover the T cell population. Part of the pool was stimulated in 
vitro for 4 hours with PMA and ionomycin to enumerate cells that were either IFN-γ or 
IL-17 producers. The other fraction was used to enumerate Foxp3
+
 CD4
+
 T cells. In the 
experiment shown, there was an average 12.3 fold reduction of Th1 cells and a 9.4 fold 
reduction of Th17 cells in treated compared to control corneas. The numbers of Foxp3
+
 T 
cells were almost identical in corneal pools from treated and control animals (Fig. 4C). 
Two additional experiments provided a similar pattern of results. Taken together our 
results show that a consequence of TCDD treatment was to increase the ratio of total 
numbers of Foxp3
+
 CD4
+
T cells to both, Th1 and Th17 cells (Fig. 4D).  
Parallel studies of a similar design were performed with T cells isolated from the 
draining lymph nodes (DLN) and spleen collected from the same animals used for the 
corneal studies. The results shown in figure 5A-D demonstrate that Th1 and Th17 cell 
frequencies and total numbers per organ were significantly reduced in TCDD recipients 
when compared to controls. However the frequencies of Foxp3
+
 Tregs, compared as a 
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fraction of total CD4
+
 T cells, were increased in treated animals when compared to 
controls.  Additionally, when the ratio of total numbers of Treg per T effectors was 
compared to controls, a significant increase in the number of Treg per Th1 or Th17 cells 
in the TCDD treated mice was evident (Fig. 5E). 
To compare levels of IFN-γ and IL-17 produced by CD4+ T cells from infected 
and treated or untreated mice, sorted CD4
+ 
T cells were isolated from DLNs on day 10 pi 
and stimulated in vitro with PMA/ionomycin. When comparing the number of IFN-γ and 
IL-17 secreting CD4
+
 T cells by ICCS, averages were reduced for both in TCDD treated 
animals (Fig. 5G). Similarly IFN-γ secreting levels measured by ELISA were reduced 2.9 
fold as a consequence of TCDD treatment (Fig. 5H). 
 
AhR signaling promotes Treg induction but suppresses Th1 and Th17 cells generation 
in vitro 
Results from the previous section indicated that there was a shift in the balance 
between Tregs and Teffectors towards Tregs, as well as a reduction in the production of 
proinflammatory cytokines. To further determine how TCDD could change the balance 
of Treg to Teffectors, naïve splenocytes from DO11.10RAG2
-/-
 (98% naïve CD4
+
 T cells) 
animals were stimulated in vitro with plate bound anti-CD3 and anti-CD28, in the 
presence of IL-2. Cultures were either untreated or treated with graded amounts of TCDD 
(from 0.1µM to 0.25µM). Cultures with 0.25 µM of TCDD significantly triggered the 
conversion of approximately 6.2% of CD4
+
 T cells into Foxp3
+
 CD4
+
 T cells, as 
compared to 0.3% in the untreated controls (Fig. 6B). 
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Other cultures were TCR stimulated in a cytokine cocktail reported to induce 
either Th1 or Th17 cells in the additional presence of different doses of TCDD. The 
outcome was a significant decrease in both Th1 and Th17 cell induction (Fig. 6C-D) with 
the highest TCDD dose studied (0.6µM) causing a disappearance of the majority CD4
+
 T 
cells from the cultures (data not shown). Taken together, our results indicate that 
activation of AhR signaling by TCDD can induce some CD4
+
 T cells to become Foxp3
+
, 
but it is inhibitory to the generation of IFN-γ+ CD4+ and IL-17+ CD4+ T cells. 
 
Differential proliferation of Treg over Foxp3
- 
CD4
+
 T cells in TCDD treated mice 
To determine if TCDD had differential effects on Foxp3
+
 and Foxp3
-
 CD4
+
 T cell 
proliferation, Foxp3-GFP mice were infected and some treated with TCDD on day 5 pi. 
After an injection of BrdU on day 8 pi, experiments were terminated on day 9 and 
proliferation of both Foxp3
-
CD4
+ 
and Foxp3
+
 cells was detected by BrdU incorporation. 
Our results show that TCDD treatment significantly reduced the proliferative response of 
the Foxp3
-
 CD4
+
 T cell population in both corneas and lymphoid tissue, but was without 
significant inhibitory effects on the Foxp3
+
 CD4
+
 T cell population. Instead, the effect of 
TCDD on Foxp3
+
 cells in the cornea was to cause a modest increase in proliferation (Fig. 
7A-B). These effects could explain in part the balance between Tregs and T effectors in 
corneal lesions. 
 
Induction of apoptosis of Foxp3
-
 CD4
+
 T cells but not of Treg after TCDD treatment 
Prior studies had shown that TCDD administration in vivo causes thymocytes to 
undergo apoptosis [26]. We determined if apoptosis of Foxp3
-
 CD4
+
 T cells could 
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account for the reduced numbers of T effectors. We performed experiments with CD4
+
 T 
cells isolated from DLN or spleen on day 8 pi from HSV infected Foxp3-GFP mice. Cells 
were cultured ex vivo in the presence of TCDD for 5 hours and apoptosis of Foxp3
-
 and 
Foxp3
+
 CD4
+
 T cells was measured using Annexin-V staining. The result showed a dose 
dependent increase in the apoptosis of Foxp3
-
CD4
+
 T cells, but no significant apoptosis 
of Foxp3
+
CD4
+
 T cells (Fig. 8A and C). Notably, there was no difference in the 
frequencies of Tregs with the addition of different concentrations of TCDD as compared 
to media (Fig. 8B-C). Taken together, these results indicate that AhR signaling by 
TCDD, can promote the apoptosis of Foxp3
-
 CD4
+
 T cells in vitro, but did not cause the 
same effect in Foxp3
+
 Treg. 
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Discussion 
Stromal keratitis is a blinding immunopathological lesion induced by ocular 
infection with HSV [1,2,3]. Novel treatment procedures are needed to replace the current 
long-term use of antivirals and corticosteroids, which have unwanted side effects 
[27,28,29]. A key to controlling the severity of SK lesions is to suppress the activity of T 
cells that orchestrate lesions and enhance the representation of cellular and humoral 
events that inhibit effector cell function. In this report, we have evaluated the use of a 
novel approach to achieve lesion control in a murine model of SK. We demonstrate that 
modulation of AhR signaling with a single dose of a synthetic stable molecule (TCDD) 
causes cellular changes in the cornea after HSV infection that account for significantly 
reduced SK lesion severity. The outcome of therapy was reduced effector Th1 and Th17 
cells that orchestrate lesions, a reduction of neutrophils that are mainly responsible for 
damage to the cornea, as well as an increase in the representation of Foxp3
+ 
Treg. 
Accordingly, when the ratio of Treg per T effectors was compared to controls, a 
significant increase in the number of Treg per Th1 as well as Th17 cells in the TCDD 
treated mice was evident. Foxp3
+
CD4
+
 T cells are assumed to function by inhibiting the 
inflammatory effects of T effectors either directly, or by the generation of counter 
inflammatory molecules [30]. Since a single administration of TCDD provided effective 
treatment that lasted for as long as one month, this approach could represent an effective 
novel therapy for a lesion that is a common cause of human blindness. 
Aryl hydrocarbon receptors are found in animals in many levels of the 
evolutionary scale. They can recognize numerous low molecular weight synthetic 
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chemicals as well as a list of endogenous ligands, some of which are photoproducts of 
tryptophan breakdown [24,31]. Several cell types express AhR that includes some, but 
not all cells, involved in innate and adaptive immunity [32]. Our own interest in AhR 
ligands stemmed from recent reports that synthetic AhR agonists had antiinflammatory 
activity [9,15]. Moreover, the dioxin TCDD can provide long-term activation of the AhR 
since it is resistant to metabolic degradation [25]. As a consequence, a single 
administration can result in long-term effects on immune mediated diseases. A recent 
report using the animal model of multiple sclerosis, EAE, showed disease suppression 
when animals were pretreated with TCDD [9]. The diminished lesions in treated animals 
were correlated with expansion of the Foxp3
+
 CD4
+
 T cell population and the levels of 
some cytokines produced by effector cells were reduced.  The expansion of the Treg 
population was explained in part by conversion of naïve T cells to become Treg as could 
be demonstrated in vitro. In our studies too, we observed that a single TCDD 
administration was an effective means of reducing SK ocular lesions, but with our model 
the outcome appeared to be more the consequence of suppressed numbers of Th1 and 
Th17 T cells that orchestrate SK, than any notable effect on the expansion of Tregs. 
Accordingly, the cytokine producing cells in lesions were reduced several fold in treated 
animals, whereas Treg numbers remained approximately the same in treated and controls. 
We did confirm the Weiner group [9] observations that TCDD can cause some naïve T 
cells to convert and become Foxp3
+ 
in vitro, but in our hands this was a modest effect. 
This notwithstanding, it could be that the relative increase in Treg in the SK lesions of 
treated animals was the explanation for the reduced lesions, the Treg acting by inhibiting 
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the functions of effectors as well as producing anti-inflammatory cytokines such as IL-
10. 
Equally possible, however, was that the reduced lesions were the direct 
consequence of the fewer numbers and less functional effectors in the corneas of treated 
animals. Such effectors would be less able to recruit inflammatory cells such as 
neutrophils that are considered responsible for much of the tissue damage of SK [33,34]. 
The reduced numbers of effectors would likely arise either, or both, from an inhibitory 
effect of TCDD on effector cell proliferation and differentiation, or be explained by the 
drug causing apoptosis of effectors. The latter effect could readily be demonstrated by in 
vitro studies with TCR stimulated CD4
+ 
T cells cultured with TCDD. In addition, Foxp3
- 
CD4
+
 T cells from treated animals proliferated less in vivo than did cells from control 
animals. In some reports TCDD was shown to prematurely terminate the proliferation 
and decrease the survival of CD4
+
 T cell, although differential effects on T cell subsets 
were not investigated [35]. Nevertheless, since regulatory T cells may be more resistant 
to apoptosis than conventional T cells [32,36] frequencies of Tregs would be expected to 
increase when other T cell populations are depleted.  
The reduced number of effector cells present in drug treated animals in our studies 
were also functionally impaired in their ability to mediate inflammatory reactions. 
Accordingly, ex vivo stimulation of DLN cells from drug-treated mice produced lower 
levels of some proinflammatory cytokines as well as chemokines responsible for 
neutrophil recruitment than cells from control animals. During in vitro studies, AhR 
ligation was shown to affect the differentiation of T helper subsets, behaving differently 
under identical culture conditions depending on the ligand used. TCDD for example, was 
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shown to trigger the conversion of Foxp3
-
CD4
+
 into Foxp3
+
CD4
+ 
without the need for 
TGF-β addition [9,37], to dampen Th17 differentiation [37] and to increase the frequency 
of IL-17 secreting cells induced by TGF-β plus IL-6 [38]. On the other hand, FICZ under 
identical culture conditions promoted Th17 differentiation, but not Treg differentiation 
[37,38]. Other ligands too, such as kynurenine (the first tryptophan metabolite of the IDO 
pathway), was shown to optimally generate Tregs in the presence of TGF-β [39].  In our 
in vitro experiments not only did we find a conversion of naïve T cells into Tregs, but 
also provided support for the notion that the TCDD interfered with the primary induction 
of both Th1 and Th17 cells. Thus, in the presence of TCDD, TCR stimulated naïve CD4
+
 
T cells cultured in conditions to cause their differentiation into either Th1 or Th17 cells, 
resulted in significant suppression. As it currently stands, our mechanistic experiments 
cannot establish which is the major explanation for the in vivo anti-inflammatory effects 
of TCDD against SK. Further investigations are needed and are underway.   
The use of TCDD represents a potentially valuable approach to control SK since a 
single injection provided an excellent level of lesion control for at least a month p.i. So 
far our results can only be considered as quasi-therapeutic since treatment was begun 5 
days after infection, a time when most infectious virus has been eliminated but clinical 
lesions are yet to become evident [1,2,3]. Moreover, we elected to study only the dose 
shown to be effective in an autoimmune disease model [9]. Since in some studies the 
outcome of treatment has been shown to be dose dependent [35] similar dose response 
studies are warranted in the SK system and these are planned. Nevertheless, our approach 
does stand in contrast to most other investigations where treatment was begun prior to 
disease induction, or before natural disease is expected to occur. With ocular HSV 
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infection in mice, such an early treatment approach would not be recommended because 
when TCDD was given one day after infection up to half of the animals succumbed to 
lethal infection of the CNS. Others too have observed that TCDD administration in viral 
infections can result in increased mortality [40,41,42]. For example, with influenza A 
virus infection AhR activation by the administration of TCDD decreased the survival 
time to lethal infection and resulted in mortality with a non lethal dose of the virus 
[42,43]. The cause of lethality was unclear since TCDD treated animals cleared the virus 
from the lungs as well as a non-treated mice [44]. More than likely animals succumbed to 
lung pathology associated with increased neutrophilia found in the lungs of TCDD 
treated mice [21,45]. Curiously however, in our model TCDD administration reduced the 
numbers of neutrophils in the infected corneas. 
Aesthetically, the use of TCDD for therapy, a molecule often castigated as an 
environmental pollutant, may have minimal appeal. However, the use of a natural ligand 
for AhR such as FICZ that can be metabolized by the body may not represent a good 
option. Several studies using FICZ have observed that inflammatory lesions can be 
exacerbated by such a treatment [9,23]. For example, in the studies on EAE by Weiner 
and colleagues [9], FICZ treatment resulted in more severe lesions.  A similar outcome 
was reported too by Stockinger and colleagues [23]. In our own studies, we observed no 
beneficial, or in fact harmful, effects when we treated HSV infected mice with FICZ. One 
reason AhR ligation with certain ligands can cause enhanced inflammatory lesions is that 
Th17 T cells, mainly responsible for mediating some inflammatory diseases, express high 
levels of AhR [22]. Consequently, ligation of AhR on Th17 cells can cause cell 
expansion and the production of cytokines that contribute to tissue damage [9,23]. In the 
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SK model, Th17 cells appear to play only a minor role in SK pathogenesis [46], which 
may explain our failure to observe adverse effects of FICZ therapy.  It could be however 
that using non-toxic ligands such as 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic 
acid methyl ester which induces Foxp3
+
 T CD4
+
 T cells and suppresses EAE [47] could 
lead to a more acceptable therapeutic approach for SK. 
In conclusion, our results are consistent with the observation that modulation of 
AhR signaling through the use of TCDD plays a role in influencing the expression of SK 
lesions. The mechanisms involved to explain the outcome were multiple, and involve a 
change in the balance between effector and regulatory T cells. We anticipate that 
manipulating AhR signaling, preferable with non-toxic ligands, could represent a useful 
approach to control an important cause of human blindness. 
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FIGURE 3.1. Preventive administration of TCDD diminishes SK 
severity. 
C57BL/6 animals infected with 1 x 10
4
 PFU of HSV were given either TCDD or vehicle 
IP on day 1 pi or FICZ or vehicle IP from day 1 to day 11 pi. The disease progression 
was analyzed throughout time in a blinded manner using a scale described in materials 
and methods. A, The progression of SK lesion severity was significantly reduced in the 
group of mice treated with TCDD as compared with control mice. Kinetics of SK 
severity is shown. B, The progression of angiogenesis was significantly reduced in the 
group of mice treated with TCDD as compared with control mice. Kinetics of 
angiogenesis lesion severity is shown. C, Individual eye scores of SK lesion severity and 
angiogenesis on day 14 pi. D, Percentage of encephalitis through time in control and 
TCDD treated mice. Herpetic encephalitis is an acute inflammation of the brain caused 
by HSV-1 and in mice gives clinical signs such as lethargy, ruffled fur, and hindlimb 
paralysis [54,55] E, Eye swabs were taken from infected corneas from treated and control 
animals using sterile swabs on day 1, 3 and 6 pi or corneal tissue on day 6 pi and titration 
was performed by standard plaque assay as described on material and methods. Titers 
were calculated as log10 pfu/ml. F, Kinetics of SK lesion scores in mice treated with FICZ 
or vehicle.  Data are representative of 3 independent experiments and show mean values 
± SEM(n=10 mice/group). P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*) 
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FIGURE 3.2. Therapeutic administration of TCDD diminishes SK 
severity. 
C57BL/6 animals infected with 1 x 10
4
 PFU of HSV were given either TCDD or vehicle 
IP on day 5 pi. The disease progression was analyzed throughout time. A, The 
progression of SK lesion severity was significantly reduced in the group of mice treated 
with TCDD as compared with control mice. Kinetics of SK severity is shown. B, 
Individual eye SK scores on day 10, 12 and 15 pi. C, The progression of angiogenesis 
was significantly reduced in the group of mice treated with TCDD as compared with 
control mice. Kinetics of angiogenesis lesion severity is shown. D, Individual eye 
angiogenesis scores on day 10, 12 and 15 pi. E, Eyes were processed for cryo-sections on 
day 15 pi. Hematoxylin and eosin staining was carried out on 6-μm sections and pictures 
were taken at different microscope augmentations. F, The progression of SK lesion 
severity was significantly reduced in the group of mice treated with TCDD as compared 
with control mice. Kinetics of SK severity is shown up to day 28 p.i.  Data are 
representative of 3 independent experiments and show mean values ± SEM (n=14 
mice/group). P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*) 
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FIGURE 3.3. TCDD treatment reduces cellular infiltration and cytokine 
levels in corneas of HSV infected animals.  
Wild-type C57BL/6 mice corneas were scarified and infected with 1 x 10
4
 PFU of HSV-1 
in PBS and mice were given either TCDD or vehicle IP on day 5 pi. A, Representative 
FACS plots of CD45
+
 cells infiltrated in the corneas of control (left) and day 5 TCDD 
treated (right panel) mice are shown. B, Representative FACS plots and percentages of 
CD4
+
 T cells gated on total CD45
+
 cells infiltrated in the corneas of control (left) and day 
5 TCDD treated (right panel) mice are shown. C, CD11b
+
 Ly6G
+
 polymorphonuclear 
neutrophils gated on total CD45
+
 cells infiltrated in the corneas of control (left panel) and 
day 5 TCDD treated (right panel) mice are shown.. D, Numbers of total CD45
+
 cells, 
neutrophils gated on total CD45
+
 cells and CD4
+
 T cells gated on total CD45
+
 cells 
infiltrated per cornea of control and TCDD treated mice. Data are the combination of 3 
independent experiments and show mean values ± SEM (n=9 and each sample is 
representative of 2 corneas). Total number of CD45
+
 cells recovered from corneal 
samples varied and ranged from around 20,000 to 80,000 cells. E, Relative fold change in 
the mRNA expression of various cytokines (IL-1 , TNF-α, IL-6, IFN- , IL-17, IL-10, 
CXCL9, CXCL10, CXCL11, CCL20) was examined and compared between control and 
TCDD day 5 treated mice on day 15 pi by Q-RTPCR. mRNA levels for the different 
cytokines in mock infected mice were set to one and used for the relative fold 
upregulation. Data represents means ± SEM from two different independent experiments 
(n=2 and each sample is representative of 8 corneas). Day 15 pi corneal samples were 
used for all the experiments. P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*) 
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FIGURE 3.4. TCDD treatment shifts the balance from T efferctors to T 
regulatory cells after HSV infection.  
C57BL/6 animals infected with 1 x 10
4
 PFU of HSV were given either TCDD or vehicle 
IP on day 5 pi. Mice were sacrificed and corneas were collected on day 15 pi A, 
Representative FACS plots gated on CD4
+
 T cells for IFN-γ and IL-17 secreting cells 
from pooled corneas stimulated with PMA/ionomycin during 4 hours from control and 
day 5 TCDD treated mice. B, FACS plots of Foxp3
+
CD4
+
 cells from pooled corneas from 
control and day 5 TCDD treated mice.  C, Frequencies and total numbers of CD4
+ 
T cells, 
Th1, Th17 and Tregs in infected corneas from control and day 5 TCDD treated animals. 
D, Cell ratios for total numbers of Tregs per Th1 cell and Tregs per Th17 cell. Data are 
representative of 3 independent experiments and show mean values ± SEM (n=6 and 
each sample is representative of 2 corneas). P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*). 
Day 15 pi corneal samples were used for the experiments.  
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FIGURE 3.5. Differential effect of TCDD treatment on Treg and 
effector T cells in lymphoid organs of TCDD treated animals.  
C57BL/6 animals infected with 1 x 10
4
 PFU of HSV were given either TCDD or vehicle 
IP on day 5 pi. A, Representative FACS plots and percentages for IFN-γ and IL-17 
secreting T cells gated on CD4
+
 T cells from day 15 DLNs stimulated with 
PMA/ionomycin during 4 hours from control and day 5 TCDD treated mice. FACS plots 
of CD4
+
Foxp3
+
 cells from DLNs from control and day 5 TCDD treated mice. B, 
Representative FACS plots and percentages for IFN-γ and IL-17 secreting T cells gated 
on CD4
+
 T cells from day 15 spleens stimulated with PMA/ionomycin during 4 hours 
from control and day 5 TCDD treated mice. FACS plots of CD4
+
Foxp3
+
 cells from 
spleens from control and day 5 TCDD treated mice. C, Cell numbers of CD4, Th1, Th17 
and Tregs in DLNs stimulated with PMA/ionomycin. D, Cell numbers of CD4, Th1, 
Th17 and Tregs in spleen stimulated with PMA/ionomycin. E, Cell ratios for total 
numbers of Tregs per Th1 cell and Tregs per Th17 cell in DLN and spleen. F, IFN-  and 
IL-17 protein levels analyzed by ELISA from control and TCDD treated infected DLN 
on day 15 pi. G, FACS plots, percentages and cell numbers for IFN-γ and IL-17 secreting 
T cells gated on CD4
+
 T cells from day 10 DLN samples, purified for CD4
+
 T cells and 
stimulated with PMA/ionomycin during 4 hours. H, IFN-  protein levels analyzed by 
ELISA from control and TCDD treated infected DLN at day 10 pi, purified for CD4
+
 T 
cells and stimulated with PMA/ionomycin during 4 hours. Data are representative of 3 
independent experiments and show mean values ± SEM (n=12). P ≤ 0.001(***), P ≤ 
0.01(**), P ≤ 0.05(*). 
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FIGURE 3.6. TCDD promotes Treg differentiation whereas diminishes 
Th1 and Th17.  
Naïve spleenocytes obtained from DO11.10RAG2
-/- 
mice were differentiated under 
different conditions for 5 days for the in vitro generation of different T cell subsets 
followed by ICS of Foxp3
+, 
IFN-γ, and Il-17. A, Representative FACS plots of 
splenocytes stained for CD62L and CD44 gated on CD4
+
 T cells. B, Representative 
FACS plots showing the induction of Foxp3
+
CD4
+
 T cells under the indicated incubation 
conditions. Bar diagram showing the percentages of Foxp3
+
CD4
+
 T cells under the 
indicated conditions C, Frequencies of IFN-γ+CD4+ T cells differentiated in the presence 
of TCDD at different concentrations. Bar diagram showing the percentages of IFN-
γ+CD4+ T cells under the indicated conditions. D, Frequencies of IL-17+CD4+ T cells 
cells differentiated in the presence of TCDD at different concentrations. Bar diagram 
showing the percentages of IL-17
+
CD4
+
 T cells under the indicated conditions 
Experiments were repeated at least 3 times.  Data were analyzed using one-way ANOVA 
test with Dunett’s post hoc test settings and show mean values ± SEM.  P ≤ 0.001(***), P 
≤ 0.01(**), P ≤ 0.05(*). 
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FIGURE 3.7. Differential proliferation of Treg over Foxp3
-
CD4
+
 T cells 
in TCDD treated mice after HSV-1 infection.  
A, Control and day 5 TCDD treated GFP-Foxp3
+ 
mice were given BrdU intraperitoneally 
one day before termination and the next day (day 9 pi) corneas, DLNs and spleens were 
analyzed for the frequencies of Foxp3
+
CD4
+
 and Foxp3
-
 CD4
+
 T cells that incorporated 
BrdU; representative FACS plots for cells are shown. B, The bar diagram shows the 
frequencies of Treg and Foxp3
-
CD4
+
 T cells labeled for BrdU in cornea, DLN and 
spleen. Data are representative of 3 independent experiments and show mean values ± 
SEM (n=12). P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*).  
 
 
 
 
 
 
 
 
 
  132 
  
 
 
 
 
  133 
FIGURE 3.8. TCDD causes apoptosis of Foxp3
-
CD4
+
 T cells but not 
Tregs.  
Foxp3-GFP mice were HSV-1 infected and sacrificed on day 8pi. A, Induction of in vitro 
apoptosis by different concentrations of TCDD on Foxp3
-
CD4
+ 
T cells but not on 
Foxp3
+
CD4
+
 T cells. Cells isolated from spleens and DLNs of HSV-1 infected mice were 
cultured ex vivo in the presence of RPMI or RPMI with different concentrations of TCDD 
for 5h and thereafter stained for annexin V, representative FACS plots showing annexin-
V expression on gated CD4
+
 T cells. B, Representative FACS plots of Foxp3
+
CD4
+
 T 
cells in splenocytes and DLNs cells from HSV-1 infected mice treated in vitro with 
different concentrations of TCDD for 5h. C, Bar diagram showing the percentages of 
Annexin V
+
Foxp3
-
CD4
+
, Anexin V
+
Foxp3
+
CD4
+
 and Foxp3
+
CD4
+
 under the indicated 
conditions in the DLN is shown. Data are representative of 3 independent experiments. 
Data were analyzed using one-way ANOVA test with Dunett’s post hoc test settings and 
show mean values ± SEM (n=12).  P ≤ 0.001(***), P ≤ 0.01(**), P ≤ 0.05(*). 
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CHAPTER III 
CONTROLLING HERPETIC STROMAL KERATITIS 
BY MODULATING LYMPHOTOXIN-ALPHA-
MEDIATED INFLAMMATORY PATHWAYS 
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Research described in this chapter is a slightly modified version of submitted to Journal 
of Leukocyte Biology by Tamara Veiga Parga, Fernanda Gimenez, Sachin Mulik, Eugene 
Chiang, Jane L Grogan and Barry T Rouse. 
 
Veiga-Parga T, Gimenez F, Mulik S, Chiang E, Grogan JL and Rouse BT.  
Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated 
inflammatory pathways. (Journal of Leukocyte Biology- submitted) 
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Abstract 
 
Herpes simplex virus 1 infection of the eye can result in stromal keratitis (SK), a 
chronic immunoinflammatory lesion in the cornea that is a significant cause of human 
blindness. A key to controlling the severity of SK lesions is to identify cellular and 
molecular events responsible for tissue damage and to modulate their functions. This 
report evaluates the role of lymphotoxin (LT)- , a proinflammatory cytokine that could 
be involved in mediating tissue damage during SK. We demonstrate that in response to 
HSV infection, both LT-  and LT-b transcripts are detectable at high levels 48 hours 
postinfection, suggesting roles for both the secreted homotrimer LT-a3 and the 
membrane-bound LT-a1b2 heterotrimer in SK pathology. Using a corneal stromal 
fibroblast cell line, both LT-a3 and LT-a1b2 were found to have proinflammatory roles 
by stimulating production of chemokines. Treatment of mice with a depleting anti-LT-a 
mAb during the clinical phase of the disease significantly attenuated SK lesions. In 
treated mice, corneal expression of proinflammatory molecules and chemokines was 
reduced, as were numbers of cornea-infiltrating proinflammatory cells, particularly Th1 
cells. The protective effect of anti-LT-a mAb was abrogated with a mutant version of the 
mAb that lacks Fc receptor binding activity, indicating that depletion of LT-expressing 
cells was responsible for efficacy. These data demonstrate that LT-expressing cells, such 
as Th1 cells, mediate SK, but that secreted LT-a3, while contributing to pathogenesis, is 
not sufficient to drive disease. 
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Introduction 
 Ocular infection with herpes simplex virus type 1 (HSV-1) can result in a chronic 
immunoinflammatory lesion in the corneal stroma, which is a significant cause of human 
vision loss [1, 2]. The pathogenesis of stromal keratitis (SK) involves numerous events, 
but studies indicate that lesions are mainly orchestrated by CD4
+
 T cells. These CD4
+
 T 
cells recognize virus-derived peptides or even altered self-proteins that are unmasked 
once the cornea is damaged [3-5]. Therefore, SK lesions largely represent 
immunopathological reactions and these are managed by prolonged treatment with 
antiviral and anti-inflammatory drugs [6, 7]. Since there is no currently available 
treatment that removes latent virus from infected persons, periodic new lesion episodes 
are to be expected [3, 8, 9].  Current therapies can be problematic, but there is hope that 
identifying components of lesion pathogenesis and targeting them for therapy could 
represent a more acceptable form of therapy. One approach could be to eliminate or 
inhibit the activated proinflammatory CD4
+
 T cells that are mainly responsible for 
orchestrating SK lesions [10-14]. 
 Lymphotoxin-alpha (LT- ) is a member of the TNF superfamily. It can be found as 
a soluble homotrimer, known as LT- 3, which binds TNF receptors and has been shown 
to have a proinflammatory role in different animal models of inflammatory diseases [15]. 
LT-  can also be complexed with LT-  as a heterotrimer, known as LT- 1 2, which 
binds to its cognate receptor LT-bR and is expressed on the cell surface of some 
lymphocyte populations, including activated CD4
+
 Th subsets such as Th1 and Th17 cells 
[16, 17]. Targeting LT-  with a mAb was shown to be efficacious in some murine 
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models of autoimmune diseases that involve the inflammatory effects of T cells [16, 17]. 
Since there are parallels in pathogenic mechanisms in some autoimmune diseases and 
SK, we speculated that the administration of anti-LT-a mAb could modulate disease in a 
mouse model of SK. 
In the present report we demonstrate that in the initial inflammatory response to 
HSV-1 infection LT-  is upregulated in the cornea. We also show that the soluble 
version of LT-  has a proinflammatory role in vitro in a corneal cell line. When mice 
with early lesions of SK were treated with anti-LT-a mAb, lesions were significantly 
diminished and inflammatory cells and their products were markedly reduced compared 
to control Ab treated animals. Similar inhibitory effects were not achieved with a mutant 
Ab that lacked Fc receptor binding activity. This indicated that the protective effect 
involved depletion of LT-  expressing cells. Since activated Th1 cells are one of the 
predominant pathogenic cells expressing LT-a, our data confirms the role of these cells in 
mediating SK, but also demonstrates that secreted LT-a3 is not sufficient to drive disease. 
Additionally, since this mAb treatment was effective to limit the severity of SK when 
initiated during the clinical phase, the strategy may be worth exploring in the natural 
disease situation. 
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Materials and Methods 
Ethics statement 
 This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Research Council. All 
animals were housed in Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC)-approved animal facilities. The protocol was approved by the 
Institutional Animal Care and Use Committee of the University of Tennessee (Public 
Health Service Assurance number 63-R-0105). HSV-1 eye infection was performed 
under deep anesthesia (avertin), and all efforts were made to minimize animal suffering. 
Mice, virus, and cell lines 
 For the experiments, C57BL/6 female 5 to 6 weeks old were used. All 
manipulations were done in a laminar flow hood. All experimental procedures were in 
complete agreement with the Association for Research in Vision and Ophthalmology 
resolution on the use of animals in research. HSV-1 RE was used in all procedures. Virus 
was grown and titrated on Vero cells (American Type Culture Collection no. CCL81) 
using standard protocols. The virus was stored in aliquots at -80°C until use. MK/T-1 cell 
line (immortalized keratocytes from C57/BL6 mouse corneal stroma) was kindly gifted 
by Dr. Reza Dana (Schepens Eye Research Institute and Department of Ophthalmology, 
Harvard Medical School, Boston, MA). 
Corneal HSV-1 infection and clinical observations 
            Corneal infections of C57BL/6 mice were done under deep anesthesia induced by 
intra-peritoneal injection in tribromoethanol (avertin) as previously described [18]. 
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Corneas were scarified with a 27-gauge needle, and a 3-µl drop containing the specific 
viral dose (1x10
4
 PFU) was applied to the eye. Eyes were examined on different days 
postinfection (p.i.) with a slit-lamp biomicroscope (Kowa Company, Nagoya, Japan) 
measuring the progression of SK lesion severity and angiogenesis of individual mice. The 
scoring system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate 
corneal opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea 
and corneal ulcer; +5, corneal rupture and necrotizing keratitis [19].  
Treatment 
 Mice were treated subcutaneously (SC) with LT- -specific mAb (anti-LT- ) 
(6mg per kg body weight), LT- .Fc-MT (anti-LTMT) (6mg per kg body weight), CTLA-
4 fusion protein (CTLA-4.Ig) (6mg per kg body weight),  or isotype control ragweed-
specific mouse IgG2a antibody (6mg per kg body weight) 3 times per week, starting on 
day 6 p.i. [17].   
Histopathology 
 Eyes from isotype and treated mice were extirpated on day 15 p.i. and snap frozen 
in OCT compound (Miles; Elkart, IN, USA). Six-micron-thick sections were cut and air 
dried in a desiccation box. Staining was performed with hematoxylin and eosin (Richard 
Allen Scientific; Kalamazoo, MI, USA). 
Flow cytometry 
 Single cell suspensions were prepared from cornea and cervical DLNs of mice at 
different time points p.i. Corneas were excised, pooled group wise, and digested with 60 
U/ml Liberase (Roche Diagnostics; Indianapolis, IN, USA) for 35 min at 37°C in a 
humified atmosphere of 5% CO2. After incubation, corneas were disrupted by grinding 
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with a syringe plunger on a cell strainer, and a single cell suspension was made in 
complete RPMI 1640 medium. 
The single cell suspensions obtained from corneas and DLNs were stained for cell 
surface molecules. All steps were performed at 4°C. A total of 1 X 10
6
 cells were first 
blocked with an unconjugated anti-CD32/CD16 mAb for 30 min in FACS buffer. After 
washing with FACS buffer, CD4-PerCP (clone RM4.5, BD Biosciences, San Jose, CA, 
USA) mAb was added for 30 min on ice. Neutrophils were defined as 
CD45
+
Ly6G
+
CD11b
+
 using CD45-allophycocyanin (clone 30-F11, BD Biosciences), 
CD11b-PerCP (clone MI/70, BD Biosciences) and Ly6G-FITC (clone 1A8, BD 
Biosciences). Finally, the cells were washed three times and re-suspended in 1% para-
formaldehyde. The stained samples were acquired with a FACS Calibur (BD 
Biosciences; San Jose, CA, USA), and the data were analyzed using FlowJo software. 
For corneas, total cell numbers were calculated by acquiring the totality of the sample 
and taking into consideration total number of corneas in the sample.  
 To enumerate the number of IFN-γ-producing CD4+ T cells, intracellular cytokine 
staining was performed as previously described [13]. In brief, 10
6 
freshly isolated lymph 
node and corneal cells were cultured in U-bottom 96-well plates. For in vitro induced 
cultures, cells were left unstimulated or stimulated with anti-CD3 (3 μg/ml) and anti-
CD28 (1 μg/ml) for 5 h in the presence of brefeldin A (10 µg/ml). Subsequently, cell 
surface staining was performed, followed by intracellular cytokine staining with anti-
IFN- -FITC (clone XMG1.2, BD Biosciences), using a Cytofix/Cytoperm kit (BD 
Pharmingen) in accordance with the manufacturer’s recommendations. The fixed cells 
were resuspended in 1% paraformaldehyde prior to data acquisition.  
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MK/T-1 cell assay 
 Immortalized corneal stromal fibroblast (MK/T-1) cells were stimulated in vitro 
with different concentrations of rmLT- 3 (R&D Systems; Minneapolis, MN, USA) in 
DMEM supplemented with 5% FBS for 6 h at 37
0
C in 5% CO2. The effect of LT- -
specific mAb and anti-LTMT in blocking rmLT- 3 was confirmed by addition of the 
Abs to the wells at 0.1 M. Cells were collected for gene expression analysis. 
Reverse transcriptase PCR (RT-PCR) 
 Cultured MK/T-1 cells were lysed, and total mRNA was extracted using RNeasy 
Mini Kit (Qiagen; Valencia, CA, USA). RT-PCR was performed to detect the presence of 
mRNA transcripts of various molecules (LT- , LTβR, TNFR1, TNFR2). cDNAs were 
amplified by PCR and were resolved on 1% agarose gel. The PCR primers used were the 
following:  
LT R, F 5’-CCAGGACAAGGAATACTACGAG-3’ and R 5’-GGACACAGTTGACGTCAGTATC-3’; 
TNFR1, F 5’-GAGAAGAGGGATAGCTTGTGTC-3’ and R 5’-GGTGTTCTGAGTCTCCTTACAG-3’; 
TNFR2, F 5’-CCAAGGACACTCTACGTATCTC-3’ and R 5’-CTACTGCATCCTGGGATTTCTC-3’ 
Real-time PCR (Q-RT-PCR) 
 RNA was extracted from cells and tissue using TRIzol LS reagent (Invitrogen; 
Carlsbad, CA, USA). Total cDNA was made with 500 ng of RNA using oligo(dT) 
primer. Q-RT-PCR was performed using SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) with an iQ5 RT-PCR detection system (Bio Rad, 
Hercules, CA, USA) using 5 µl cDNA for 40 cycles. The expression levels of different 
molecules were normalized to β-actin using the Δ threshold cycle method calculation. For 
corneas, relative expression between mock-infected samples and isotype or treated 
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samples from day 15 p.i. were calculated using the 2
-ΔΔCt
 formula: Ct = Ctsample - 
Ctreference. Here, ΔCt is the change in cycling threshold between the gene of interest and 
the “housekeeping” gene β-actin, where Ctsample was the Ct value for any treated or 
isotype samples from day 15 p.i. normalized to the β-actin gene, and Ctreference was the 
Ct value for the mock-infected samples (scratched and infected only with PBS) also 
normalized to β-actin. Each of the samples was run in duplicate to determine sample 
reproducibility, and a mean Ct value for each duplicate measurement was calculated. For 
MK/T-1 cells, relative expression between control (non-exposed) samples and samples 
exposed to LT- 3 with or without anti-LT-  and anti-LTMT, or exposed to LT- 1β2 
were calculated using the 2
-ΔΔCt
 formula: Ct = Ctsample - Ctreference. Here, ΔCt is the 
change in cycling threshold between the gene of interest and the “housekeeping” gene β-
actin, where Ctsample was the Ct value for any sample exposed to LT- 3 with or without 
anti-LT-  and anti-LTMT, or exposed to LT- 1β2 normalized to the β-actin gene, and 
Ctreference was the Ct value for the control samples also normalized to β-actin. Each of 
the samples was run in duplicate to determine sample reproducibility, and a mean Ct 
value for each duplicate measurement was calculated.  
The PCR primers used were the following: 
 actin, F 5’-CCTTCTTGGGTATGGAATCCTG-3’ and R 5’-
GGCATAGAGGTCTTTACGGATG-3’; IL-1 , F  5’-GAAATGCCACCTTTTGACAG-
3’ and R 5’- CAAGGCCACAGGTATTTTGT-3’; IFN- , F  5’-
GGATGCATTCATGAGTATTGC-3’ and R 5’-GCTTCCTGAGGCTGGATTC-3’; 
CXCL-9, F 5’-CAAGCCCCAATTGCAACAAA-3’ and R 5’- 
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TCCGGATCTAGGCAGGTTTGA-3’; CXCL-10, F 5’-
TGCTGGGTCTGAAGTGGGACT-3’ and R 5’- AAG CTT CCC TAT GGC CCT CA-
3’; MCP-1/CCL2, F 5’-TGGCTCAGCCAGATGCAGT-3’ and R 5’-
TTGGGATCATCTTGCTGGTG-3’; KC/CXCL1, F 5’-GTGTTGCCCTCAGGGCC-3’ 
and R 5’-GCCTCGCGACCATTCTTG-3’; 
Statistical analysis 
 Most of the analyses for determining the level of significance were performed 
using one-way ANOVA test. Values ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 were 
considered significant. Results are expressed as means ± SEM. For some experiments, as 
mentioned in the figure legends, an unpaired two-tailed Student t test was applied. 
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Results 
Changes in LT-  and LT-  as a consequence of HSV-1 infection 
 To investigate the potential role of LT-  in mediating tissue damage during SK, 
mice were ocularly infected with HSV and then expression levels of both LT-  and LT-  
were measured in pools of corneal extracts at various time points p.i. Expression levels of 
both LT-  (Figure 1A) and LT-  (Figure 1B) were readily detectable in infected corneas 
with a first peak on day 2 p.i. (average 300-fold and 150-fold increase compared to 
scratched but uninfected controls, respectively). However, expression of both LT-a and 
LT-b was rapidly downregulated, as by day 3 mRNA expression levels for both 
molecules were at control levels. The initial burst of LT-a and LT-b transcriptional 
activity was followed by a second wave, with marked increases in mRNA levels in the 
infected group detectable in day 15 samples (LT-  with an average of 40 fold and LT-  
with an average of 120 fold). In summary, expression levels of LT-  and LT-  were 
increased after HSV-1 infection. Both peaks correlated with the infiltration of 
proinflammatory cells that we see after HSV-1 infection of the cornea [4], and that have 
been previously described as populations that express LT-  [17].  
 
LT- 3 acts as a proinflammatory cytokine in vitro 
 LT-  can be found as a soluble homotrimer, LT- 3, and can also be complexed 
with LT-  as a membrane-bound heterotrimer, LT- 1 2. To determine whether LT- 3 
acts as a proinflammatory mediator in the cornea, we used the corneal stromal fibroblast 
cell line MK/T-1. MK/T-1 cells express both TNFR1 and TNFR2 at the transcriptional 
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level (Figure 2A), indicating that this cell line was appropriate for in vitro assays 
assessing the ability of LT-a3 to stimulate TNFR-mediated signaling pathways. Culture 
of MK/T-1 cells with recombinant LT- 3 resulted in significant induction of 
transcriptional activity of CXCL-10 and KC (Figure 2B, C), chemokines involved in the 
migration of pathogenic cells into the cornea [4].  A mAb specific for LT-  (anti-LT- ) 
has been shown to bind to both LT-a3 and LT- 1 2, but only fully blocks the interaction 
between LT-a3 and TNFR and not between LT- 1 2 and LT-bR [17]. Addition of anti-
LT-  to MK/T-1 cells stimulated with LT-a3 completely inhibited the secretion of 
CXCL-10 and KC, as did an Fc-effectorless mutant of the anti-LT-  mAb which has 
been shown to have similar binding/blocking properties as the wild-type mAb [17]. 
MK/T-1 cells stimulated with LT- 1 2 were similarly induced to express CXCL-10 and 
KC (Supplementary Figure 1), but inhibition assays were not possible due to the inability 
of anti-LT-a mAb to fully block LT- 1 2/LT-bR interaction.  These results suggest that 
LT- , as both LT-a3 and LT-a1b2, may act in vivo to induce chemokines that further 
recruit inflammatory cells to the infected cornea.  
 
LT- -specific mAb decreases SK induced immunopathology and inhibits cellular 
infiltration in infected corneas 
 To evaluate whether LT-a has a role in mediating SK immunopathology, the anti-
LT-a and anti-LTMT mAbs were used to treat mice in a herpetic SK model. Mice 
infected with HSV were treated 3 times a week, starting on day 6 p.i. when lesions start 
to become evident. As seen in Figure 3, treatment with anti-LT-a significantly decreased 
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the severity of SK lesions when compared to the isotype control Ab group. SK scores 
(Figure 3A) were significantly lower in the anti-LT-a group (2.6 ± 0.2 vs 3.8 ± 0.3 in the 
isotype treated animals, p = 0.01), eyes exhibited visible reductions in lesion severity 
(Figure 3B), and histology showed decreased cellular infiltration and inflammation in the 
cornea (Figure 3C). The protective effects of anti-LT-a were similar to those conferred by 
CTLA-4.Ig treatment, which was used as positive control for assessing T cell 
contribution to SK. In contrast to anti-LT-a treatment, anti-LTMT did not have an effect 
on SK outcome, with lesions having similar severity as those in the isotype control group.  
 As anti-LTMT is an Fc-effectorless mutant of wild-type anti-LT-a, and is thus 
unable to mediate antibody-dependent cellular cytotoxicity [17, 20], the efficacy of anti-
LT-a treatment appears to dependent on depletion of LT-a-expressing cells. To determine 
whether treatment with anti-LT-a reduces pathogenic cell numbers in the mouse SK 
model, pools of corneas were collected on day 15 p.i. from anti-LT- , anti-LTMT and 
isotype treated animals and processed for recovery of inflammatory cells for 
enumeration. CD4
+
 T cells are primary drivers of SK, and anti-LT-a treatment 
significantly reduced the frequency of CD4
+
 T cells in the cornea and CD4
+
 T cell 
numbers on an absolute basis compared to isotype control, having similar effects as 
CTLA-4.Ig (Figure 4A). In contrast, anti-LTMT treated animals showed no difference 
CD4
+
 T cell frequencies or numbers, indicating that the effects of anti-LT-  were 
mediated through Fc-dependent mechanisms specifically directed at LT- -expressing 
cells.  
Within the CD4
+
 T cell population, Th1 cells are the primary orchestrators of the 
inflammatory reaction [4]. To determine if Th1 cells were selectively affected by anti-
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LT-  treatment, cells were isolated from corneal tissues and draining lymph nodes on 
day 15 p.i., following treatment during the clinical phase of disease. Using intracellular 
cytokine staining for IFN-g to identify Th1 cells, anti-LT-a treatment was found to 
significantly reduce the frequency and absolute number of Th1 cells in the cornea (Figure 
4B) as well as draining lymph node (Figure 4C), again having a comparable effect as 
CTLA-4.Ig treatment. As observed with bulk CD4
+
 T cells, anti-LTMT treatment showed 
no effect on Th1 cells when compared to the isotype treated group in neither corneas nor 
DLNs.  
 
LT- -specific mAb treatment reduces proinflammatory responses in the cornea 
To assess the effect of anti-LT-a treatment on proinflammatory cytokine and 
chemokine production in SK, mRNA was prepared from corneal extracts on day 15 p.i. 
following treatment that was started on day 6 p.i. As shown in Figure 5, samples from 
animals treated with anti-LT-  showed a five-fold reduction of IL-1β when compared to 
isotype treated animals. Additionally, levels of chemokines involved in neutrophil (KC) 
and monocyte (MCP-1) migration, lymphocyte migration (CXCL-9 and CXCL-10), as 
well as IFN-  were significantly decreased in anti-LT-  treated animals. CTLA-4.Ig 
treatment had a similar effect as anti-LT-a, suggesting that the production of 
proinflammatory cytokines and chemokines in the cornea of diseased animals was 
dependent on T cell activation. In contrast, anti-LTMT treatment showed no significant 
expression differences in any molecules when compared to the isotype treated group, 
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indicating that depletion of LT-a-expressing cells, and not blockade of LT-a3/TNFR-
mediated signaling, is required for inhibition of proinflammatory responses.  
To determine if the reduction in chemokine expression in the corneas of anti-LT-a 
treated mice had functional consequences in terms of impacting migration of infiltrating 
cells, the frequency and cell numbers of neutrophils in the cornea was analyzed. KC is a 
chemokine involved in neutrophil recruitment, and neutrophils infiltrating the cornea are 
responsible for the tissue damage associated with SK [4]. Consistent with the finding that 
anti-LT-a treatment reduced expression of KC, neutrophil frequencies and total cell 
numbers were significantly lower in the anti-LT-a, but not anti-LTMT group compared to 
the isotype control (Supplementary Figure 2). 
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Discussion 
 Stromal keratitis is a blinding lesion of the eye set off by HSV-1 with its 
pathogenesis primarily involving events that are common to several autoimmune 
diseases. Indeed, some groups have strongly advocated that the syndrome could involve 
autoreactive events, but the exact mechanisms that occur, particularly in human lesions, 
have not been resolved [4, 5].  Many chronic tissue lesions are controlled using powerful 
drugs such as corticosteroids that have unwanted side effects [21, 22]. More acceptable 
approaches to therapy could come from targeting specific cells that contribute to tissue 
damage. In the blinding lesion that results from HSV infection, damage to the cornea is 
thought to result from a T cell orchestrated reaction set off by the infection [3, 5, 23].
 Accordingly, a logical approach to therapy could be to target the pathological T 
cells and inhibit their activity. In this report we show that this objective can be met by 
administering a mAb specifically recognizing LT-  during ongoing lesions. We showed 
that anti-LT-  mAb treatment significantly reduced SK lesions and markedly reduced the 
numbers of inflammatory cells and their products in the ocular responses, and this effect 
was similar to blockade of T cell activation with CTLA-4.Ig. The effect was assumed to 
target primarily LT-  inflammatory CD4
+
 T cells, particularly the Th1 subset, since a 
mAb lacking the Fc receptor binding activity was without therapeutic activity even 
though the mAb could neutralize the proinflammatory effects of the soluble LT-  
homotrimer in vitro. Our results indicate that treatment with mAb to LT-  can 
beneficially influence the outcome of ongoing SK lesions in a model system with the 
treatment holding promise as a new approach to control an important cause of human 
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blindness.  
 The biology of LT-a is intriguing in the context of SK. Soluble LT-a3 binds to 
TNFR1 and TNFR2, and ligation initiates signaling through the canonical NF-kB 
pathway, which controls many inflammatory genes [24]. Membrane-bound LTa1b2 binds 
to LT-bR, with engagement activating both the canonical and non-canonical NF-kB 
pathways [24]. Unlike TNF, which is produced by a wide array of cells, LT-a3 
expression is restricted and predominantly produced by activated CD4
+
 Th cells, namely 
Th1 and Th17 cells. Similarly, LT-a b2 is expressed on the surface of these Th subsets, 
and serves as a marker identifying these populations. Thus, LT-a can induce production 
of inflammatory cytokines and chemokines either through direct interaction between cells 
expressing LT-a1b2 with those expressing LT-bR within the cornea such as fibroblasts, 
epithelial cells and myeloid cells. Additionally, soluble LT-a3 can exert its influence 
distally on ubiquitously expressed TNFR1 or the more restricted TNFR2.  
 We utilized a depleting anti-LT-a mAb that has the capacity to bind both LT-a3 and 
LT-a1b2 as well as block LT-a3/TNFR signaling to evaluate whether LT itself has a role 
in mediating SK or if LT-producing cells are critical. We showed a significant therapeutic 
effect of anti-LT-  when used to treat SK and demonstrated that it is the pathogenic T 
cells, and not their production of LT-a3, that are responsible for SK. CD4
+ 
T cell 
numbers, particularly the Th1 subset, were significantly reduced in anti-LT-a treated 
animals, while this effect was abrogated with the Fc-effectorless mutant mAb.  The anti-
LTMT was similar to wild-type mAb in its ability to inhibit LT-a3-induced activation of 
corneal stromal fibroblasts in vitro, thereby suggesting that LT-a3 is not likely to play a 
prominent role in eliciting proinflammatory responses in SK in vivo. The efficacy of 
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wild-type anti-LT-a but not the mutant Ab suggests that LT-a expressing cells were 
specifically targeted for depletion. While we attempted to directly measure depletion of 
LT-a expressing cells by flow cytometry of cells harvested from corneas ex vivo, this 
proved to be challenging. Previous reports demonstrated that depletion of LT-expressing 
cells could be observed in in vitro recall assays using specific antigens [17], a technique 
not available to us with the SK model.  Our contention that depletion of pathogenic cells 
expressing surface LT is responsible for efficacy of anti-LT-a is bolstered by similar 
findings in other models of inflammation such as collagen-induced arthritis, delayed-type 
hypersensitivity and experimental autoimmune encephalomyelitis [17]. 
 While it is generally accepted that Th1 cells are the primary mediators of the 
inflammatory reaction, neutrophils are primarily responsible for causing the actual tissue 
damage [4]. Anti-LT-a treatment significantly reduced corneal expression of various 
chemokines, including the neutrophil chemoattractant KC. Correspondingly, neutrophil 
numbers were also found to be lower in anti-LT-a treated corneas. This is likely due to 
the anti-LT-a mediated reduction of pathogenic Th1 cells and not direct depletion of 
neutrophils, as CTLA-4.Ig similarly impacted both KC expression and neutrophil 
infiltration. The ability of anti-LT-a to eliminate activated Th1 cells and of CTLA-4.Ig to 
inhibit activation of Th1 cells [25] results in similar outcomes: a reduction in the 
secretion of Th1 proinflammatory factors that drive downstream pathogenic signals. 
 
 The anti-LT-a mAb used in these studies did not allow us to assess the role of LT-
a1b2 interaction with LT-bR in SK. Unlike its ability to completely block LT-a3/TNFR, 
this mAb, as well as the Fc mutant, was shown to only partially block LT-a1b2/LT-bR 
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[17]. MK/T-1 cells responded to in vitro stimulation with LT-a1b2 with robust 
production of chemokines, suggesting that LT-a1b2-expressing CD4
+
 T cells infiltrating 
the corneas upon infection with HSV-1 can generate a milieu of proinflammatory 
cytokines and chemokines through direct contact with stromal cells, leading to infiltration 
of pathogenic cells that results in lesions associated with SK. As treatment with anti-LT-a 
mAb depletes those cells expressing surface LT-a1b2, the potential for LT-a1b2 binding 
to LT-bR is also eliminated. However, since the ability of TNFR1 to induce 
proinflammatory responses is relatively stronger than that of LT-bR [26], it is unlikely 
that the LT-a1b2/LT-bR pathway significantly contributes to pathology given that LT-
a3/TNFR does not. 
 In addition to Th1 cells, Th17 cells also express LT-a1b2 on the cell surface and 
secrete LT-a3 [17]. However, we did not focus on Th17 responses since in the SK model, 
Th17 cells appear to play only a minor role in SK pathogenesis, and these cells never 
outnumber Th1 [27]. Our observations add further evidence to the notion that Th1 cells 
play a critical role during HSV-1 infection. We can also infer from our data that therapies 
that target Th1 responses in the phase of active lesions could be beneficial to the outcome 
of the disease. Unlike CTLA-4.Ig, which broadly inhibits all T cell activation, anti-LT-a 
mAb only depletes activated pathogenic Th cells. Our studies demonstrated that similar 
efficacy could be achieved with such a targeted approach.  Regulatory T cells (Tregs) 
also play an important role in protecting the host from ocular immunopathology [28] and 
expanding their numbers can result in diminished SK. Moreover, Tregs do not express 
LT- 1 2, and therefore are not depleted by the administration of anti-LT-  [17]. 
Combination therapies using anti-LT-  and a drug that could boost or expand Treg 
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responses [12, 29-31] could prove even more efficacious in controlling and diminishing 
SK lesions, and these studies are currently being evaluated.  
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FIGURE 4.1. Changes in LT-  and LT-  as a consequence of HSV-1 
infection 
WT mice corneas were scarified and infected with 10
4
 PFU HSV-1 in PBS or mock 
infected with only PBS (scratched uninfected control mice). Corneas were harvested from 
infected mice at indicated time points p.i. and from mock infected mice at 24 hours p.i. 
(A) Kinetic analysis for the expression of LT-  mRNA by Q-RT-PCR at different days 
p.i. At each time point, six corneas were collected and pooled for mRNA extraction. The 
expression levels of LT-  were normalized to β-actin using ΔCt calculation. Relative 
expression between control and infected groups was calculated using the 2−ΔΔCt formula. 
Data are representative of three independent experiments and show mean values ± SEM 
(each sample is representative of  6 corneas). (B) Kinetic analysis for the expression of 
LT-  mRNA by Q-RT-PCR at different days p.i. At each time point, six corneas were 
collected and pooled for mRNA extraction. The expression levels of LT-  were 
normalized to β-actin using ΔCt calculation. Relative expression between control and 
infected groups was calculated using the 2−ΔΔCt formula. Data are representative of three 
independent experiments and show mean values ± SEM (each sample is representative of  
6 corneas).  
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FIGURE 4.2. LT- 3 induces the expression of proinflammatory 
cytokines by corneal stromal fibroblast cells.  
(A) Agarose gel analysis of TNFR1 (381; lane 1); and TNFR2 (304; lane 2) cDNA from 
in vitro grown MK/T-1 cells. Lane M, marker and Lane 3, negative control. (B) MK/T-1 
cells were stimulated with 100ng/ml of LT- 3 or media alone for 6 h. MK/T-1 were also 
stimulated with 100ng/ml of LT- 3 in the presence of anti-LT-  or anti-LTMT at 0.1 M. 
Cells were collected and pooled for analysis of KC and CXCL-10 mRNA expression by 
Q-RT-PCR. Data are representative of three independent experiments and show mean 
values ± SEM. ***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of significance were 
analyzed by one-way ANOVA test with Dunnett’s post hoc test settings. 
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FIGURE 4.3. LT- -specific mAb treatment during clinical stages of the 
disease decreases SK lesion severity.  
Mice infected with HSV-1 were given either isotype control, LT- -specific mAb, anti-
LTMT or CTLA-4.Ig s.c. starting on day 6 p.i., and treated 3 times a week until the 
termination day (day 15 p.i.). (A) SK lesion severity was significantly decreased in the 
groups of mice treated with anti-LT-  when compared to isotype or anti-LTMT treated 
mice on day 15 p.i. Individual eye scores of SK lesion severity on day 15 p.i. are shown. 
(B) Representative eye photos show decreased SK lesion severity from anti-LT-  treated 
mice starting on day 6 p.i. compared with isotype and anti-LTMT treated mice. (C) Eyes 
were processed for cryo-sections on day 15 p.i. Hematoxylin and eosin staining was 
carried out on 6-μm sections, and pictures were taken 40X magnification. Representative 
eye sections show decreased cellular infiltration in anti-LT-  treated mice when 
compared to  isotype and anti-LTMT treated animals. Data are representative of three 
independent experiments and show mean values ± SEM (n = 12-15 mice/group). ***p ≤ 
0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by one-way 
ANOVA test with Dunnett’s post hoc test settings. 
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FIGURE 4.4. LT- -specific mAb treatment decreases cellular 
infiltration in corneas of HSV-1 infected animals.  
Mice infected with HSV-1 were treated with isotype control, anti-LT- , anti-LTMT or 
CTLA-4.Ig starting on day 6 p.i., 3 days a week until the termination day (day 15 p.i.). 
(A) Representative FACS plots and numbers of CD4
+
 T cells isolated from corneas of 
treated mice are shown. (B). Representative FACS plots and numbers of IFN-γ-secreting 
cells gated on CD4
+
 T cells infiltrated in the cornea on day 15 p.i. and stimulated with 
anti-CD3/anti-CD28 for 5 h. (C) Representative FACS plots and numbers of IFN-γ-
secreting cells gated on CD4
+
 T cells infiltrated in DLN on day 15 p.i. and stimulated 
with anti-CD3/anti-CD28 for 5 h. Data are representative of three independent 
experiments and show mean values ± SEM (n = 10-12 mice/group). ***p ≤ 0.001,**p ≤ 
0.01,*p ≤ 0.05. Statistical levels of significance were analyzed by one-way ANOVA test 
with Dunnett’s post hoc test settings. 
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FIGURE 4.5. LT- -specific mAb treatment decreases cytokine and 
chemokine levels in corneas of HSV-1-infected animals.   
Mice infected with HSV-1 were given either isotype, anti-LT- , anti-LTMT, or CTLA-
4.Ig starting on day 6 p.i. 3 times a week until the termination day (day 15 p.i.). Mice 
were sacrificed on day 15 p.i., and corneal extracts were collected for measuring 
inflammatory factors using Q-RT-PCR. Relative fold change in mRNA expression of the 
proinflammatory cytokine IL-1β, of the chemokines KC, MCP-1, CXCL9, and CXCL10, 
and of the proinflammatory molecule IFN-  were examined. mRNA levels for the 
different cytokines in mock-infected mice were set to one and used for the relative fold 
upregulation. Data are representative of three independent experiments and show mean 
values ± SEM (n = 12 mice/group, each sample is representative of 4 corneas). ***p ≤ 
0.001,**P ≤ 0.01,*P ≤ 0.05. Statistical levels of significance were analyzed by one-way 
ANOVA test with Dunnett’s post hoc test settings. 
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SUPPLEMENTARY FIGURE 4.1. LT- 1b2 induces the expression of 
proinflammatory cytokines by corneal stromal fibroblast cells.  
 
MK/T-1 cells were stimulated with 100ng/ml of LT- 1b2 or media alone for 6 h. MK/T-
1 were also stimulated with 100ng/ml of LT- 1b2  in the presence of anti-LT-  or anti-
LTMT at 0.1 M. Cells were collected and pooled for analysis of KC and CXCL-10 
mRNA expression by Q-RT-PCR. Data are representative of three independent 
experiments and show mean values ± SEM. ***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. 
Statistical levels of significance were analyzed by an unpaired two‐ tailed Student t test. 
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SUPPLEMENTARY FIGURE 4.2. LT- -specific mAb treatment 
decreases neutrophil infiltration in corneas of HSV-1 infected animals.  
Mice infected with HSV-1 were treated with isotype control, anti-LT- , anti-LTMT or 
CTLA-4.Ig starting on day 6 p.i., 3 days a week until the termination day (day 15 p.i.). 
Representative FACS plots and numbers of CD11b
+
Ly6G
+
 polymorphonuclear 
neutrophils gated on total CD45
+
 cells isolated from corneas of treated mice are shown. 
Data are representative of three independent experiments and show mean values ± SEM 
(n = 10-12 mice/group). ***p ≤ 0.001,**p ≤ 0.01,*p ≤ 0.05. Statistical levels of 
significance were analyzed by one-way ANOVA test with Dunnett’s post hoc test 
settings. 
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CONCLUSION 
 SK is a chronic immunoinflammatory lesion in cornea with a complex 
pathogenesis. Discoveries of novel pathways and molecular participants in the 
pathogenesis would provide new targets for designing therapeutics. Because T cells have 
a major role in SK pathogenesis, approaches that either inhibit or eliminate T effectors or 
boost Treg responses would be of interest. 
The work described in this dissertation evaluates the effects of some of these 
strategies on the modulation of SK lesion severity by focusing on different aspects of T 
cell immunity and using therapies that specifically target this type of cells. Consequently, 
specifically targeting T cells responses during SK can be beneficial in preventing and/or 
controlling SK immunopathology.  
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